

## Index

- abscesses, 17, 189. *See also* carbuncles; furuncles
- acanthamebiasis, in HIV infection, 193–194
- Acanthamoeba* spp., 121
- Acanthaster planci* (crown of thorns) starfish, 173
- acellular pertussis (DTaP) vaccination, 294
- acetaminophen, for HSV 1 and 2 infections, 277
- Acinetobacter baumannii*, 189
- Ackerman, A. Bernard, 6
- acne miliaris necrotica, 262
- Acquired Immune Deficiency Syndrome (AIDS). *See also* HIV-related skin infections; Kaposi's sarcoma (KS)
- acid-fast bacilli in, 72
- anergy, presence of, in, 4
- coccidioidomycosis and, 144
- cryptococcus with, 111
- cutaneous tuberculosis with, 73
- diabetes and, 8
- disseminated histoplasmosis (DH) and, 104
- esophageal infections with, 221
- historical background, of, 185
- Mycobacterium avium intracellulare* with, 292
- pbmycosis with, 108
- progressive vaccinia and, 23
- pulmonary tuberculosis in, 60
- systemic tropical mycoses and, 96
- tuberculosis and, 60
- Acremonium* spp., 113, 270–272
- actinias, reactions to, 169–171
- Actinomadura madurae* grains, 97, 156
- Actinomyces*, 3
- Actinomyces israelii*, 294
- actinomycosis, 294
- acute disseminated miliary tuberculosis (tuberculosis cutis miliaris acuta generalisata), 67
- acute exanthem, 145
- of HIV infection
- cytomegalovirus, 187
- Epstein-Barr virus, 187
- herpes simplex virus (types 1 and 2), 186
- human herpes virus 8, 188–189
- pox virus, 187
- varicella-zoster virus, 186–187
- acute febrile neutrophilic dermatosis (Sweet's syndrome), 146
- acute infections, primary signs of, 8
- acute miliary cutaneous tuberculosis, 60, 74
- acute necrotizing ulcerative gingivitis, 294–295
- acute paronychial infections, 268–269
- acyclovir
- for congenital herpes simplex, 30
- for genital herpes, 319
- for hand-foot-and-mouth disease, 282
- for herpes simplex virus, 200, 277
- for herpes virus B, 34
- for herpes zoster, 31
- for HSV-1/HSV-2, 29
- oral, for HSV, 186
- for oral hairy leukoplakia, 187, 279
- for suspected neonatal HSV, 225
- for varicella zoster virus, 31, 201
- for VZV, 187
- Aedes aegypti* mosquito, 92, 95, 151, 152
- African Americans
- and lepromatous leprosy, 77
- and pediculosis, 230
- and pseudofolliculitis barbae, 216
- and tinea capitis, 43
- agent formulary for topical therapy, 11
- albendazole
- for cysticercosis, 129
- for echinococcosis, 129
- for enterobiasis, 128
- for filariasis, 124
- for loiasis, 124
- for mansonielliasis, 128
- for onchocercosis, 176
- for trichinellosis, 128
- Alcyonidrium gelatinosum* bryozoans, 175
- Alcyonidrium hirsutum* bryozoans, 175
- Alcyonidrium topsenti* bryozoans, 175
- algae/Bryozoans and aquatic dermatoses
- algae, 174
- Bryozoans, 175
- protothecosis, 174–175
- allopurinol, for Old World CL, 144
- allylamine, for tinea unguium (onychomycosis), 52
- Almeida, Floriano de, 151
- Alternaria* spp., 113, 270
- aluminum acetate (Burrow's solution), for impetigo, 261–262
- Amblyomma americanum* (lone star tick), 215
- Amblyomma Cajennense* (Cayenne tick), 323
- American Society for Dermatologic Surgery survey, 303
- American Thoracic Society, 292
- American trypanosomiasis, 123
- amikacin with tetracycline, for protothecosis, 175
- aminoglycosides
- for ecthyma gangrenosum, 215
- for nocardiosis, 198
- amitriptyline for post-herpetic neuralgia, 31
- amorolfine
- nail lacquers, for tinea unguium, 219
- topical, for tinea unguium, 236
- amoxicillin
- complications from, 33, 278–279
- for genital bite wounds, 317
- for Lyme disease, 215
- for perianal streptococcal dermatitis, 212
- amphotericin B
- for candidiasis, 191
- for chromoblastomycoses, 156
- for coccidioidomycosis, 148
- for cryptococcosis, 112
- for cutaneous cryptococcus, 191
- for entomophthoromycosis, 111
- with 5-fluorocytosine
- for aspergillosis/cryptococcosis/candidiasis, 114
- for histoplasmosis, 192
- IV, for protothecosis, 175
- for leishmaniasis, 297
- liposomal, for mucormycosis, 110
- for mycetoma, 157
- for Old World CL PVA failures, 143
- for paracoccidioidomycosis, 109
- intravenous, 159
- for penicilliosis, 193
- for rhinosporidiosis, 104
- for sporotrichosis, 102
- amyloidosis (primary) and Hansen's disease, 78
- Anaerobic streptococci, 250
- Anaplasma phagocytophilum*, 215
- Ancylostoma braziliensis* (hookworm of dogs and cats), 125, 127, 176
- Ancylostoma caninum*, 125, 176
- Anemonia sulcata* actinia, 168–170
- anergic leishmaniasis, 151
- angular cheilitis (perleche), 221
- anogenital disease
- bowenoid papulosis, 26
- condyloma acuminatum, 26
- verrucous carcinoma, 26–27
- anogenital warts, 319

## 330 — Index

- anopheline (malaria-carrying) mosquitos, 95
- anthrax, 295
- Anthraxin test, 4
- antibiotics. *See* individual antibiotics
- anticonvulsants. *See* carbamazepine; gabapentin; pregabalin
- antifungal medications. *See also* fluconazole; griseofulvin; itraconazole; ketoconazole; terbinafine
- for pityriasis versicolor (PV), 52–53
- for seborrheic dermatitis/pityriasis capitis, 256
- for tinea capitis, 51
- for tinea corporis/cruris/faciei, 50–51
- for tinea pedis/manuum, 47–50
- for tinea unguium (onychomycosis), 51–52
- antifungal shampoos, 51, 217, 218, 256, 258
- antihistamines
- for folliculitis, 189
- for mite symptom control, 231
- for pediculosis capitis itch control, 260
- antimalarials, for ENL treatment, 84
- anti-retroviral therapy
- for acute exanthem, 186
- for hairy leukoplakia, 279
- for KS, 34
- Aphrodite aculeata* polychaete, 176
- Apophysomyces elegans*, 109
- aquatic dermatoses from biotic organisms
- from algae/Bryozoans
- algae, 174
- Bryozoans, 175
- protothecosis, 174–175
- from aquatic bacteria
- erysipeloid, 179
- mycobacterium marinum, 178–179
- from aquatic worms
- cercariae, 175
- contact with bait, 176
- leeches, 176
- nematodes, 176–177
- onchocercosis, 175–176
- polychaetes, 176
- from arthropods, 174
- from coelenterates, 167–172
- actinia reactions, 169–171
- jellyfish reactions, 168–169
- physaliae/corals/hyroid reactions, 172
- sea bather's eruptions, 171–172
- from echinoderms
- sea urchins, 172–173
- starfish, 173–174
- from fish, 177–178
- historical background, 167
- from mollusks, 174
- from sponges, 174
- aquatic worms and aquatic dermatoses
- cercariae, 175
- contact with bait, 176
- leeches, 176
- nematodes, 176–177
- onchocercosis, 175–176
- polychaetes, 176
- arboviruses. *See* arthropod-borne infections
- Argentinian hemorrhagic fever, 153
- Aristotle
- on contagiousness of phthisis, 59
- on parasites, 117
- arthropod-borne infections. *See also* Chagas' disease; Dengue fever; ectoparasite infestation; mouse-borne diseases; sandfly-borne diseases; tick-borne diseases; Yellow fever
- diagnosis, 93–94
- epidemiology, 93
- general information, 92
- historical background, 92–93
- pitfalls and myths, 95
- therapy, 94–95
- arthropods, lesions from, 174
- Asians
- and lepromatous leprosy, 77
- syphilis rates in pregnant women, 222
- aspergillosis, 7, 47, 109, 192, 206, 207
- clinical presentation, 288
- diagnosis, 288
- at hospital sites, 206
- invasive, in AIDS, 192
- in mucormycosis, 287
- in transplant patients, 264
- treatment, 288
- Aspergillus* spp., 270–272
- asymmetry (as sign of acute infection), 8
- athletes, skin infections in
- atypical mycobacteria (swimming pool granuloma), 244
- bacterial infections
- folliculitis, 239
- furunculosis, 238–239
- gram negative hot tub folliculitis, 240
- green foot, 240
- hot foot syndrome, 240
- impetigo, 238
- pitted keratolysis, 239–240
- tropical ulcers, 240
- fungal infections
- tinea corporis gladiatorum, 243–244
- tinea pedis, 243
- historical background, 238
- parasites (cutaneous larvae migrans), 244
- viral infections
- herpes simplex
- activation, 240
- skin-to-skin transmission, 240–241
- molluscum contagiosum, 241–242
- verruca, 242
- atopic dermatitis, 21, 114, 193, 225
- atovaquone, for tularemia, 95
- atypical mycobacterioses, 6
- classification, 88–89
- Mycobacterium avium* complex, 89
- Mycobacterium chelonae-Mycobacterium abscessus* complex, 89
- Mycobacterium fortuitum* complex, 89
- Mycobacterium kansasii*, 88
- Mycobacterium marinum*, 67, 88
- Mycobacterium scrofulaceum*, 64, 74, 89
- clinical presentation, 89–90
- diagnosis, 90
- historical background, 88
- pitfalls and myths, 90–91
- therapy, 90
- autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome, 222
- Ayurveda, 59
- azidothymidine (AZT), for HIV, 185, 284
- azithromycin
- for bacillary angiomatosis, 189–190, 198
- for cat-scratch disease, 215
- for chancroid, 313
- for diphtheria, 294
- for granuloma inguinale, 315
- for syphilis, 312
- for tularemia, 95
- azoles
- for coccidioidomycosis, 148, 192
- for Old World CL, 143
- for pityriasis versicolor, 53
- for tinea unguium (onychomycosis), 52
- topical, for erythrasma, 249
- B. dermatitides*, 7
- babesiosis, 92
- bacillary angiomatosis (BA)
- in HIV, 189–190
- in transplant recipients, 197–198
- Bacillus anthracis*, 295
- Bacillus Calmette-Guerin* (BCG), 60, 67
- vaccinations of against TB, 4, 62, 65, 72–73
- bacillus Calmette-Guerin (BCG)
- vaccinations, 4
- Bacillus vincentii*, 294
- bacterial infections in athletes
- folliculitis, 239
- furunculosis, 238–239
- gram negative hot tub folliculitis, 240
- green foot, 240
- hot foot syndrome, 240
- impetigo, 238
- pitted keratolysis, 239–240
- tropical ulcers, 240
- bacterial infections in elderly patients
- cellulitis/erysipelas, 234
- herpes zoster, 235
- impetigo/folliculitis/furunculosis, 234–235
- necrotizing fasciitis, 235
- bacterial infections of the scalp
- eosinophilic pustular folliculitis, 261
- erysipelas/scalp cellulitis, 262
- folliculitis, 260
- impetigo, 261–262
- staphylococcal folliculitis, 260–261
- bacterial infections related to HIV
- bacillary angiomatosis, 189–190
- folliculitis, 189
- impetigo, abscesses, cellulitis, necrotizing fasciitis, 189
- mycobacterial infections, 189

- bacterial infections related to mucous membranes
- actinomycosis, 294
  - acute necrotizing ulcerative gingivitis, 294–295
  - anthrax, 295
  - bacterial vaginosis, 295
  - diphtheria, 293–294
  - mycoplasma pneumoniae, 296
  - noma (cancrum oris/gangrenous stomatitis), 295
  - pseudomonas aeruginosa, 295
  - rhinoscleroma, 294
  - staphylococcus, 293
  - streptococcus, 293
  - tetanus, 296
- bacterial uSSSIs. *See* uncomplicated skin and skin structure infections (uSSSIs)
- bacterial vaginosis, 295
- bacterial/viral disease in transplant recipients
- bacillary angiomatosis, 197
  - B-hemolytic streptococcus, 196–197
  - gram-negative bacilli (GNB), 197
  - historical background, 195
  - necrotizing fasciitis, 197
  - nocardiosis, 198
  - Staphylococcus aureus*, 195–196
  - vibrio vulnificus*, 197
- Bacteroides*, 250
- Baker-Rosenbach's erysipeloid, 179
- Balamuthia mandrillaris*, 121
- Barmah Forest virus (BFV), 152–153
- Bartonella*, 4, 197
- Bartonella henselae*, 189, 197, 215
- Bartonella quintana*, 92, 189, 197
- basal cell carcinoma (BCC), 303
- Basidiobolus haptosporus*, 110
- Basidiobolus ranarum*, 110
- Bayle, Gaspard Laurent, 59
- Bazin, Ernest, 69. *See also* erythema induratum of Bazin
- bedbugs, 232
- benzathine penicillin
- for endemic treponematoses, 216
  - for scarlet fever, 212
  - for syphilis, 190, 312
  - congenital, 223
- benznidazole
- for American trypanosomiasis, 123
  - for Chagas' disease, 160
- benzocaine preparations, for HSV, 277
- benzoyl peroxide, 20, 21
- benzyl benzoate
- for demodicidosis, 260
  - for scabies, 193, 260
- betadine, for impetigo, 261–262
- bifonazole
- for pityriasis versicolor, 53
  - with urea, for tinea unguium (onychomycosis), 219
- Bipolaris*, 113
- black piedra, 154, 258
- black superficial onychomycosis (BSO), 271–272
- black-dot tinea capitis, 257
- Blastomyces dermatitidis*, 105
- blastomycosis. *See also*
- chromoblastomycosis; North American blastomycosis; paracoccidioidomycosis (South American blastomycosis)
  - chromomycosis (*see* chromoblastomycosis)
  - clinical presentation, 289
  - diagnosis, 289
  - differentiation from
    - lupus vulgaris, 63, 74
    - warty tuberculosis, 65
  - in HIV infection, 193
  - keloidal blastomycosis, 102, 157
  - in mucous membrane infections, 289
  - oral itraconazole for, 47
- bleomycin injections, for verrucae vulgaris/condyloma acuminatum, 203
- blister beetles, 232
- blistering dactylitis, in children, 212
- Bolivian hemorrhagic fever, 153
- borderline lepromatous (BL) disease, 79, 83
- borderline tuberculoid (BT) leprosy, 78, 83
- Borrelia*, 4
- Borrelia burgdorferi*, 215
- Borrelia vincentii*, 294
- bowenoid papulosis, 26
- breasts, tuberculosis of, 72
- British Society for Antimicrobial Chemotherapy, 306
- British Society for Dermatological Surgery, 306
- Brucella, 3
- Brugia malayi*, 123
- Brugia timori*, 123
- bryozoans and dermatitis, 175
- bullous impetigo, 195, 211
- Bunostomum phlebotomum*, 125
- Burkitt lymphoma, 187, 279
- Buruli ulcer, 7
- Burulin intradermal reaction, 4
- Butcher's warts, 26
- butenafine
- for tinea corporis/cruris/faciei, 50
  - for tinea pedis/manuum, 47
- C. immitis*, 7
- C. neoformans*, 7
- Calymmatobacterium granulomatis*, 314
- Calymmatobacterium granulomatis* Gram-negative rod, 151, 190
- CA-MRSA. *See* community-acquired methicillin resistant *Staphylococcus aureus* (CA-MRSA)
- cancer patients and skin infections
- cutaneous infections
    - bacterial infections, 207
    - fungal infections, 207
    - viral infections, 207
  - diagnosis, 206
  - epidemiology, 206
  - historical background, 206
  - malignant infections
    - angiosarcoma, 209
    - breast cancer, inflammatory, 208–209
    - cancers metastatic to skin, 210
    - keratoacanthoma, 209–210
    - lethal midline granuloma, 209
    - leukemia cutis, 208
    - lymphoma, 208
    - squamous cell cancer, 209
    - Stewart-Treves syndrome, 209
    - verrucous carcinoma, 209
  - therapy principles for cutaneous infections, 208
- Candida*, 3
- Candida albicans*, 191, 235, 246, 271, 272, 286
- Candida dubliniensis*, 191
- Candida glabrata*, 191
- Candida krusei*, 191
- Candida parapsilosis*, 191, 271
- Candida tropicalis*, 191
- candidal onychomycosis, 221, 236
- candidiasis
- in children, 220–221
  - in diabetes mellitus, 246–247
  - in elderly patients, 235–236
  - in HIV infection, 191
- Candidin test, 4
- Capnocytophaga*, cat and dog bites from, 19
- Capnocytophaga canimorsus*, 19, 112
- carbamazepine, for post-herpetic neuralgia, 31
- carbapenems (newer generation), for MRSA strains, 20
- carbaryl, for pediculosis capitis, 259
- carbuncles, 17. *See also* furuncles
- in diabetes mellitus, 248–249
  - in folliculitis, 234, 260
  - S. aureus* as causative, 19
  - treatment of, 20
- carpal tunnel syndrome and Hansen's disease, 78
- cat and dog bites, *Pasteurella* spp. as causative, 19
- caterpillars and moths, 232
- cat-scratch disease, 6, 92, 215
- Caucasians, and lepromatous leprosy, 77
- cefixime, for gonorrhoea, 315–316
- cefoperazone sodium, for necrotizing fasciitis, 213
- ceftriaxone
- for chancroid, 313
  - for erysipeloid, 214
  - for gonorrhoea, 315–316
  - intramuscular, for meningococcal disease, 323
  - for nocardiosis, 198
  - for syphilis, 190
- cefuroxime
- for genital bite wounds, 317
  - for Lyme disease, 215
- cellulitis, 17–18
- in diabetes mellitus, 249
  - in elderly patients, 234
  - in HIV, 189
  - of lower extremity, pitfalls and myths, 21
  - S. aureus*/*S. pyogenes* as causative, 19
  - in scalp infections, 262
  - treatment of, 20

## 332 — Index

- Centers for Disease Control and Prevention  
 on arthropod-borne diseases  
 risk factors, 93  
 treatment, 94–95  
 on treatment for cutaneous TB, 73
- cephalopods, dermatoses from, 174
- cephalosporin  
 for cellulitis/erysipelas, 234  
 for erysipelas, 20  
 for folliculitis keloidalis, 262  
 for genital bite wounds, 317  
 for gonorrhoea, 316  
 for *S. aureus*, 196
- cerarial dermatitis (swimmer's itch), 130, 175
- Cercopithecus aethiops* (green monkeys), 153
- Cerqueira, Alexandre, 150
- cestodes, 128–130  
 coenurosis, 129–130  
 cysticercosis, 129  
 echinococcosis, 129  
 sparganosis, 129
- Chagas, Carlos, 159
- Chagas' disease, 123. *See also* American trypanosomiasis  
 diagnosis, 160  
 treatment, 160
- chancroid, 309, 312–313
- chemical peels, for pseudofolliculitis barbae, 216
- chemotherapy  
 for Burkitt lymphoma, 279  
 for cervical intraepithelial neoplasms, 281  
 for chromomycosis, 100  
 for cutaneous tuberculosis, 73  
 for KS, 34, 202  
 pre-bone marrow transplant, 264  
 skin infections after, 206  
 candidiasis, 221  
 ecthyma gangrenosum, 214  
 oral mucositis, 275
- chickenpox, 30, 186, 200, 235
- Chironex fleckeri* jellyfish, 169
- Chiropsalmus quadrigatus* jellyfish, 169
- Chlamydia*, 4
- Chlamydia trachomatis*, 191, 313
- chloramphenicol, for Rocky Mountain spotted fever, 324
- chlorhexidine  
 for impetigo, 261–262  
 for *S. aureus* in transplant recipients, 196  
 for skin colonization issues, 21
- chromoblastomycosis, 6, 7, 98–100  
 differentiation from warty tuberculosis, 65  
 genera differences, 99–100  
 treatment, 100
- chronic granulomatous disease, 74
- chronic hepatitis C virus (HCV), 37
- chronic mucocutaneous candidiasis (CMC), 221–222
- chronic paronychia infections, 269
- chronic traumatic lymphedema of the hands, from sea urchins, 173
- Chrysops* spp3, 124
- ciclopirox  
 for piedra, 259  
 for tinea corporis/cruris/faciei, 50  
 for tinea pedis/manuum, 47, 47–50, 236  
 for tinea unguium (onychomycosis), 219, 236  
 topical, for pityriasis versicolor, 53  
 (topical), for white piedra, 154
- ciclopirox olamine (1%), for tinea pedis/manuum, 47
- ciclopirox shampoo, 256
- cidofovir  
 for condyloma acuminata, 188  
 for herpes simplex virus, 200
- cimetidine, for verrucae vulgaris/condyloma acuminatum, 203
- ciprofloxacin  
 for cat-scratch disease, 215  
 for chancroid, 313  
 for erysipeloid, 214  
 for granuloma inguinale, 315  
 for rhinoscleroma, 294
- Cladophialophora carrionii*, 98–99
- cladosporiosis. *See* chromoblastomycosis
- Cladosporium carrionii* dematiaceous fungus, 156
- clarithromycin  
 for atypical mycobacteria, 244  
 for atypical mycobacterioses, 90  
 for bacillary angiomatous, 189–190  
 for diphtheria, 294
- clindamycin  
 for acne miliaris necrotica, 262, 262  
 for bacterial vaginosis, 295  
 for erythrasma, 214  
 for necrotizing fasciitis, 213  
 oral, for nasal carriage issues, 21  
 for perianal streptococcal dermatitis, 212  
 for pitted keratolysis, 214  
 with rifampicin, for scalp cellulitis, 263  
 topical, 20  
 for tularemia, 95
- clofazimine  
 for leprosy, 293  
 for lobomycosis, 103, 158  
 for multibacillary disease, 84
- clotrimazole  
 for erythrasma, 249  
 for pityriasis versicolor, 53  
 for tinea corporis/cruris/faciei, 50  
 for tinea pedis/manuum, 47  
 for tinea unguium (onychomycosis), 219
- cloxacillin, for carbuncles, 249
- cnidocytes (of coelenterates), 167–168
- Coccidioides immitis*, 104
- Coccidioidin test, 4
- coccidioidomycosis and the skin  
 acute exanthem, 145  
 diagnosis, 144–145  
 disseminated infection, 147  
 epidemiology, 144  
 erythema multiforme-like eruptions, 145–146  
 erythema nodosum, 145  
 historical background, 144
- in HIV infection, 192
- interstitial granulomatous dermatitis, 146–147
- pitfalls and myths, 148
- primary cutaneous coccidioidomycosis, 147–148
- serologic testing, 148
- Sweet's syndrome, 146
- treatment, 148
- coelenterates  
 and aquatic dermatoses, 167–172  
 actinia reactions, 169–171  
 jellyfish reactions, 168–169  
 physaliae/corals/hydroid reactions, 172  
 sea bather's eruptions, 171–172  
 description of actions, 167–168
- coenurosis, 129–130
- colchicine, for ENL treatment, 84
- color (as sign of acute infection), 8
- Colorado tick fever, 92
- common warts (verruca vulgaris), 25, 203, 280
- community-acquired methicillin resistant *Staphylococcus aureus* (CA-MRSA), 19, 211, 238, 262
- S. aureus* colonization from, 21
- treatment of, 20
- complement fixation (CF) test, 4
- complications  
 measles/rubeola, 36
- Condylactis aurantiaca* actinia, 170
- condyloma acuminatum (genital warts), 203
- clinical manifestations, 26
- preventative therapies, 26
- treatment, 26
- congenital cytomegalovirus, 33
- congenital HSV, 30
- congenital indifference to pain and Hansen's disease, 78
- cytomegalovirus, 224
- neonatal HSV, 224–225
- parvovirus B19, 225
- rubella, 223–224
- sypilis, 222–223
- varicella zoster, 225
- congenital rubella syndrome, 37
- conidiobolomycosis, 110
- Conidiobolus coronatus*, 110
- Conidiobolus incongruens*, 111
- Conus aulicus* shell, 174
- Conus geographus* shell, 174
- Conus gloria maris* shell, 174
- corals, reactions to, 172
- corticosteroids  
 for folliculitis, 189  
 for folliculitis keloidalis, 262  
 for scalp cellulitis, 263  
 for tinea capitis, 217  
 for trichinellosis, 128
- Corynebacterium diphtheriae*, 293
- Corynebacterium minutissimum*, 214, 249
- co-trimoxazole, for entomophthoromycosis, 111
- cowpox, 24

- Coxsackie A-16. *See* hand, foot, and mouth disease
- creatinine phosphokinase, for differentiation of necrotizing fasciitis, 8, 213
- crotamiton  
 for demodicidosis, 260  
 for scabies, 260
- crusted (ecthymatous) zoster, 186
- cryotherapy  
 for anogenital warts, 319  
 for chromoblastomycoses, 156  
 for condyloma acuminata, 188  
 for genital warts, 319  
 for KS, 202  
 for lobomycosis, 103  
 for molluscum contagiosum, 187  
 for Old World CL, 143  
 for verruca, 228  
 for verrucae vulgaris/condyloma acuminatum, 203, 228
- cryptococcal meningitis, 47, 111
- cryptococcosis, 96, 111–112, 187  
 clinical presentation, 287  
 diagnosis, 112, 287–288  
 in HIV infection, 191  
 treatment, 112, 114, 288  
 vs. molluscum contagiosum, 187
- Cryptococcus*, 4
- Culex* mosquito, 152
- Cunningham, D. D., 135
- Cunninghamaella bertholletiae*, 109
- currtage  
 for anogenital warts, 319  
 for genital warts, 319  
 for molluscum contagiosum, 23, 187  
 for verrucae vulgaris/condyloma acuminatum, 203
- Curvularia*, 113
- cutaneous infections (possibly) indicative of underlying cancer
- fungal infections  
 aspergillosis, 207  
*Rhizopus/Mucor* spp/saprophytes, 207  
*S. Aureus* of streptococcal cellulitis, 207  
 therapy principles, 208  
 viral infections  
 herpes simplex, 207  
 herpes zoster, 207  
 warts, 207
- cutaneous larva migrans, 124–125
- cutaneous pneumocystosis, 187
- cutaneous tuberculosis  
 classification, 62  
 clinical features  
 acute disseminated miliary tuberculosis, 60, 67  
 erythema induratum of Bazin, 69–70  
 erythema nodosum, 70, 75  
 lichen scrofulosorum, 68–69  
 lichen scrofulosorum (LS), 75  
 lupus vulgaris, 60, 62–64, 74  
 orificial tuberculosis, 60, 67–68, 74–75  
 papulonecrotic tuberculids, 68, 75  
 primary inoculation tuberculosis, 67  
 scrofuloderma, 60, 64  
 tuberculids, 68  
 tuberculosis gumma, 68, 74  
 tuberculosis verrucosa cutis, 60, 65, 74  
 tuberculous chancre, 60  
 diagnosis, 61–62, 73–74  
 general information, 59–60  
 histopathology, 70–71  
 historical background, 59  
 HIV with, 59, 72  
 pathogenesis, 60–61  
 pitfalls and myths of, 73–75  
 systemic involvement, 71–72  
 treatments, 73
- Cyclops*, 124–125, 129
- cyclosporine, with fluconazole, 47
- cysticercosis, 129
- cytomegalovirus (CMV), 33  
 in children, 224  
 diagnosis, 33  
 in HIV infection, 187  
 in mucous membrane infections, 279  
 in transplantation recipients, 201–202  
 treatment, 33
- da Fonseca Filho, Olympia, 151
- Dakin's solution, for skin colonization issues, 21
- dapsone  
 for leprosy, 293  
 for multibacillary disease, 84  
 for Old World CL, 144  
 for paucibacillary disease, 84
- daptomycin, for MRSA strains, 20
- Dasympus novemcinctus*, 106
- DEET (N,N-diethyl-3-methylbenzamide)  
 mosquito repellent, 95  
 for deterrence of sandflies, 137  
 for prevention of cercarial dermatitis, 130
- Demodex brevis* mite, 260
- Demodex folliculorum* mite, 260
- demodicidosis, 193, 260
- demodicidosis (of the scalp), 260
- Dengue fever, 92, 95, 151–152  
 cutaneous features, 151–152  
 treatment, 152
- dental pastes, for HSV, 277
- depilatory creams, for pseudofolliculitis barbae, 216
- Dermacentor andersoni* (Rocky Mountain wood tick), 323
- Dermacentor variabilis* (American dog tick), 323
- dermatophyte onychomycosis (of fingernails/toenails), 47, 47, 52
- dermatophytosis, 42, 53, 191, 249, 256. *See also* tinea capitis
- dermatoses, aquatic (from biotic organisms)  
 from algae/Bryozoans  
 algae, 174  
 Bryozoans, 175  
 protothecosis, 174–175  
 from aquatic bacteria  
 erysipeloid, 179  
 mycobacterium marinum, 178–179  
 from aquatic worms  
 cercariae, 175  
 contact with bait, 176  
 leeches, 176  
 nematodes, 176–177  
 onchocercosis, 175–176  
 polychaetes, 176  
 from arthropods, 174  
 from coelenterates, 167–172  
 actinia reactions, 169–171  
 jellyfish reactions, 168–169  
 physaliae/corals/hyroid reactions, 172  
 sea bather's eruptions, 171–172  
 from echinoderms  
 sea urchins, 172–173  
 starfish, 173–174  
 from fish, 177–178  
 from mollusks, 174
- desert infections, Eastern hemisphere  
 Old World cutaneous leishmaniasis, 117–118  
 clinical presentation, 138–140  
 diagnosis, 140–141  
 epidemiology, 135–136  
 historical background, 135  
 patient follow-up, 144  
 prevention, 137–138  
 transmission (sandfly vector/*Leishmania* lifecycle), 136–137  
 treatment, 141–144
- desert infections, Western hemisphere  
 coccidioidomycosis and the skin  
 acute exanthem, 145  
 diagnosis, 144–145  
 disseminated infection, 147  
 epidemiology, 144  
 erythema multiforme-like eruptions, 145–146  
 erythema nodosum, 145  
 historical background, 144  
 interstitial granulomatous dermatitis, 146–147  
 pitfalls and myths, 148  
 primary cutaneous coccidioidomycosis, 147–148  
 serologic testing, 148  
 Sweet's syndrome, 146  
 treatment, 148
- desipramine, for post-herpetic neuralgia, 31
- Dharmendra lepromin antigen, 4
- diabetes mellitus, skin infections  
 cutaneous infections  
 candida, 246–247  
 carbuncles, 248–249  
 cellulitis, 249  
 erysipelas, 249  
 erythrasma, 249  
 furuncles, 248
- dermatophyte fungal infections, 247–248
- diagnosis, 246
- epidemiology, 246
- historical background, 246
- life threatening infections  
 Fournier's gangrene, 251  
 malignant otitis externa, 251

## 334 — Index

- diabetes mellitus, skin infections (cont.)  
 necrotizing fasciitis, 250  
 rhinocerebral mucormycosis, 251  
 predisposition to, 8  
*S. aureus* colonization from, 21  
 terbinafine for, 47  
 therapy for, 252
- diabetic ketoacidosis, 110, 251, 286
- diabetic neuropathy and Hansen's disease, 78
- diaper dermatitis (monilial diaper dermatitis), 221
- Dick's test, 4
- diethylcarbamazine (DEC)  
 for filariasis, 124  
 for loiasis, 124  
 for onchocerciasis, 124
- diffuse cutaneous leishmaniasis, 4
- diloxanide, for enteric amebiasis, 121
- diphenhydramine elixir with Maalox, for HSV, 277
- diphtheria, 293–294
- diphtheria vaccination, 294
- directly observed therapy (DOTS), 73, 292
- dissecting cellulitis (of the scalp), 262–263
- disseminated herpes-zoster, 186
- disseminated histoplasmosis (DH), 104
- disseminated infection, 147
- distal subungual onychomycosis, 236
- distal/lateral subungual onychomycosis, 270
- DNA microarray technology (DNA chip technology), 6
- DNA viruses. *See also* herpes virus, various presentations  
 hepadnaviruses, 35 (*See also* hepatitis B)  
 human papillomavirus (HPV)  
 anogenital disease  
 bowenoid papulosis, 26  
 condyloma acuminatum, 26  
 verrucous carcinoma, 26–27  
 nongenital cutaneous diseases  
 Butcher's warts, 26  
 common warts (verruca vulgaris), 25  
 epidermodysplasia verruciformis (EV), 25–26  
 flat warts (verrucae plana), 25  
 palmoplantar warts (myrmecia), 25  
 nongenital mucosal disease  
 oral focal hyperplasia (Heck disease), 27
- in mucous membrane infections  
 cytomegalovirus, 279  
 Epstein-Barr virus, 278–279  
 HSV-1 and HSV-2, 276–278  
 human papilloma virus, 280–281  
 Kaposi's sarcoma, 280  
 molluscum contagiosum, 281  
 parvovirus B19, 281  
 roseola infantum, 279–280  
 varicella zoster (HSV-3), 278  
 parvoviruses, 34–35  
 pox viruses  
 cowpox, 24
- Molluscum Contagiosum* (MCV), 23  
 monkey pox, 24  
 smallpox, 23
- docosanol (10%) cream, for herpes labialis, 277
- Donovan, C., 135
- Donovania granulomatis*, 314
- doxycycline  
 for acne miliaris necrotica, 262  
 for actinomycosis, 294  
 for anthrax, 295  
 for atypical mycobacterioses, 90  
 for bacillary angiomatosis, 189–190, 198  
 for cat-scratch disease, 215  
 for ehrlichiosis, 215  
 for endemic treponematoses, 216  
 for granuloma inguinale, 191, 315  
 for Lyme disease, 215  
 for Lyme disease/rickettsial diseases, 95  
 for lymphogranuloma venereum, 191, 314  
 for Rocky Mountain spotted fever, 324  
 for syphilis, 312  
 for tick-borne disease, 95  
 for *vibrio vulnificus*, 197
- dracunculiasis, 124–125
- Dracunculus medinensis*, 124–125
- Dyptera Order of insects (vectors), 161
- Ebola virus, 153, 284
- EBV-associated large cell lymphoma, 187
- echinococcosis, 129
- Echinococcosis granulosa*, 129
- Echinococcosis multilocularis*, 129
- Echinococcosis vogeli*, 129
- echinoderms and aquatic dermatoses  
 from fish, 177–178  
 sea urchins, 172–173  
 starfish, 173–174
- econazole  
 for tinea corporis/cruris/faciei, 50  
 for tinea pedis/manuum, 47
- ecthyma, 18, 24, 229  
 in children, 211  
 diagnosis, 20  
*S. aureus*/*S. pyogenes* causative for, 19, 197  
 similarity to mucormycosis, 109  
 in varicella zoster virus, 186, 200
- ecthyma gangrenosum, 109, 197, 214–215, 295
- ecthymatous (crusted) zoster, 186
- ectoparasite infestation, 92
- Edwardsiella lineata* anemone, 171–172
- eflornithine  
 for pseudofolliculitis barbae, 216  
 for trypanosomiasis, 123
- Ehrlichia chaffeensis*, 215
- ehrlichiosis, 92
- Eikenella corrodens*, 317
- elderly people, skin infections in  
 bacterial infections  
 cellulitis/erysipelas, 234  
 herpes zoster, 235
- impetigo/folliculitis/furunculosis, 234–235  
 necrotizing fasciitis, 235
- fungal infections  
 candidiasis, 235–236  
 onychomycosis, 236  
 tinea pedis/manum, 236–237  
 historical background, 233–234
- Electra pilosa* bryozoan, 175
- electric razor shaving, for pseudofolliculitis barbae, 216
- electrocautery  
 for Butcher's warts, 26  
 for common warts, 25  
 for condyloma acuminata, 26, 188  
 for genital warts, 319  
 for lupus nodules, 73  
 for oral florid papillomatosis, 281
- electrodesiccation  
 for anogenital warts, 319  
 for molluscum contagiosum, 187  
 for oral florid papillomatosis, 281
- emetine hydrochloride, for enteric amebiasis, 121
- endemic treponematoses, in children, 215–216
- Entamoeba histolytica*, 121
- enteric amebiasis, 121
- Enterobacteriaceae, 19
- enterobiasis, 128
- Enterovirus 71. *See* hand, foot, and mouth disease
- Enteroviruses  
 hand, foot, and mouth disease, 35–36, 281–282  
 hepatovirus/hepatitis A, 36  
 herpangina, 36, 276, 282–283
- Entomophthorales* (*Zygomycosis*), 109–110
- entomophthoromycosis, 110–111
- eosinophilic pustular folliculitis (EPF), 216, 261
- epidermodysplasia verruciformis (EV), 25–26, 228
- epithelioid cell granulomas, 74
- Epstein-Barr virus (EBV)  
 clinical manifestations, 32  
 in HIV infection, 187  
 lethal midline granuloma association, 209  
 in mucous membrane infections, 278–279  
 in transplantation recipients, 201  
 treatment, 33
- equine encephalitis, 92
- erosion (as sign of acute infection), 8
- erosive pustular dermatosis (of the scalp), 263
- erysipelas, 18  
 in diabetes mellitus, 249  
 in elderly patients, 234  
 pitfalls and myths of, 21  
*S. pyogenes* as causative, 19  
 in scalp infections, 262  
 treatment of, 20
- erysipeloid (Baker-Rosenbach's erysipeloid), 179  
 in children, 214

- Erysipelothrix rhusiopathiae*, 179, 214  
erythema induratum of Bazin, 69–70  
erythema infectiosum. *See* parvovirus B19  
erythema multiforme-like eruptions, 145–146  
erythema nodosum (EN), 70, 75, 145  
erythema nodosum leprosum (ENL), 81  
erythrasma  
  in children, 214  
  clindamycin for, 214  
  from *Corynebacterium minutissimum*, 214  
  in diabetes mellitus, 249  
  Whitfield's ointment for, 214  
erythromycin  
  for actinomycosis, 294  
  for bacillary angiomatosis, 189–190, 198  
  for cat-scratch disease, 215  
  for chancroid, 313  
  for diphtheria, 294  
  for endemic treponematoses, 216  
  for erythrasma, 249  
  for granuloma inguinale, 315  
  for pitted keratolysis, 214  
  for scarlet fever, 212  
erythromycin-clindamycin double disk testing, 20  
ethambutol  
  for cutaneous TB treatment, 73  
  for pulmonary tuberculosis, 292  
*Exophiala*, 113  
*Exophiala jeanselmei*, 113  
extrapulmonary paragonimiasis, 131  
extrapulmonary tuberculosis, 5, 59  
famciclovir  
  for congenital herpes simplex, 30  
  for genital herpes, 319  
  for herpes simplex virus, 200, 277  
  for herpes zoster, 31, 264  
  for HSV-1/HSV-2, 250  
  for varicella zoster virus, 31, 201  
  for VZV, 187  
*Fasciola gigantica*, 127, 130  
*Fasciola hepatica*, 127, 130  
fascioliasis, 130  
fetal toxoplasmosis, 222  
*Fibula nolitangere* touch me not sponge, 174  
filariasis, 123–124, 150  
*Filoviridae* virus, 153  
fingernail onychomycosis, 51  
Finsen, Niels, 59  
fish and aquatic dermatoses, 177–178  
5-fluorocytosine  
  with amphotericin B  
  for aspergillosis/cryptococcosis/candidiasis, 114  
  for chromoblastomycoses, 156  
5-fluorouracil injectable gel  
  for condyloma acuminata, 188  
  for oral florid papillomatosis, 281  
  flat warts (*verrucae plana*), 25  
  treatment, 25  
*Flaviviridae* genus, 151, 152  
flaviviruses. *See* Dengue fever; hepatitis C virus  
flea-borne diseases, 231–232  
fluconazole  
  for *Balamuthia mandrillaris*, 122  
  for coccidioidomycosis, 192  
  for cryptococcosis, 112  
  for cutaneous cryptococcus, 191  
  for entomophthoromycosis, 111  
  with 5-fluorocytosine, for candidiasis/cryptococcosis, 114  
  for pityriasis versicolor, 53  
  for sporotrichosis, 102  
  for tinea capitis, 217, 258  
fluconazole (oral)  
  adverse effects, 47  
  for candidiasis, 191  
  for cryptococcal meningitis, 47  
  for dermatophyte fungal infections, 248  
  for old world leishmaniasis, 120, 143  
  for onychomycosis, 191  
  for oropharyngeal/esophageal candidiasis, 47  
  for pityriasis versicolor, 53  
  for tinea capitis, 51  
  for tinea corporis/cruris/faciei, 50–51  
  for tinea unguium (onychomycosis), 52  
  for vaginal candidiasis, 47, 248  
flucytosine  
  for *Balamuthia mandrillaris*, 122  
  for cryptococcosis, 112  
Fluorescent In Situ Hybridization (FISH), 5  
fluoroquinolones  
  for anthrax, 295  
  for CA-MRSA, 20  
  for cellulitis/erysipelas, 234  
  for malignant otitis externa, 251  
  for nocardiosis, 198  
follicular zoster, 186  
folliculitis, 17  
  in AIDS/HIV, 186, 189  
  in athletes, 239  
  carbuncles in, 234  
  in elderly patients, 234–235  
  eosinophilic pustular folliculitis, 261  
  in HIV, 189  
  hot tub folliculitis, 19, 240  
  pitfalls and myths of, 21  
  in scalp infections, 260  
  eosinophilic pustular (EPF), 261  
  staphylococcal, 260–261  
  therapies for, 20  
folliculitis decalvans, 262–263  
folliculitis keloidalis (acne keloidalis), 262  
*Fonsecaea compacta* dematiaceus fungus, 98–99, 156  
*Fonsecaea pedrosoi* dematiaceus fungus, 98–99, 156  
Fonseca's disease. *See* chromoblastomycosis  
foscarnet  
  for CMV, 187  
  for herpes simplex virus, 200  
  for HSV (in acyclovir-resistant patients), 186  
Foshay test, 4  
Fournier's gangrene, 8  
  in diabetes mellitus, 251  
  treatment, 252  
free living amebas, 121–122  
Frei's test, 4  
fulminant meningococcal disease (Waterhouse-Friderichsen syndrome), 323  
fungal infections (common)  
  diagnostic procedures, 43–44  
  epidemiology, 42–43  
  historical background, 42  
  pitfalls and myths, 53  
  therapy, 44 (*See also* antifungal medications)  
fungal infections (deep)  
  general information, 96  
  historical background, 96  
  opportunistic cutaneous infections, 114  
  pitfalls and myths, 114–116  
  subcutaneous mycosis  
  chromomycosis, 98–100  
  mycetoma, 97–98  
  rhinosporidiosis, 103–104  
  sporotrichosis, 100–102, 193  
systemic mycosis  
  blastomycosis (North American), 105–106, 193  
  cryptococcosis, 111–112, 192  
  entomophthoromycosis, 110–111  
  histoplasmosis, 104–105  
  hyalohyphomycosis, 113–114  
  mucormycosis, 109–110  
  paracoccidioidomycosis (S.A. blastomycosis), 106–109, 192  
  chronic form (adult type), 107–108  
  residual/sequel form, 108–109  
  phaeohyphomycosis, 112–113  
  zygomycosis, 109  
fungal infections in athletes  
  tinea corporis gladiatorum, 243–244  
  tinea pedis, 243  
fungal infections in children, 216–221  
  candidiasis, 220–221  
  piedra, 220  
  tinea capitis, 217–218  
  tinea cruris, 218  
  tinea faciei, 218  
  tinea imbricata (tokelau), 219  
  tinea incognito, 218  
  tinea nigra, 220  
  tinea unguium (onychomycosis), 218–219  
fungal infections in elderly patients  
  candidiasis, 235–236  
  onychomycosis, 236  
  tinea pedis/manum, 236–237  
fungal infections in mucous membrane infections  
  chronic mucocutaneous candidiasis, 286  
  endemic mycoses, 288–290  
  blastomycosis, 289  
  coccidioidomycosis, 289–290

## 336 — Index

- fungal infections in mucous membrane infections (cont.)  
 histoplasmosis, 288–289  
 paracoccidioidomycosis, 289  
 nonendemic mycoses, 286–288  
 aspergillosis, 288  
 disseminated candidiasis, 286  
 mucormycosis, 286–287  
 superficial mycoses/*Candida* spp., 284–286
- fungal infections of HIV infection  
 aspergillosis, 192  
 blastomycosis/sporotrichosis, 193  
 candidiasis, 191  
 coccidiomycosis, 192  
 cryptococcus, 191  
 dermatophytosis, 191  
 histoplasmosis, 191–192  
 paracoccidiomycosis, 192  
 penicilliosis, 192–193  
 pneumocystosis, 191
- fungal infections of the nail unit, 269–273  
 combined variants of onychomycosis, 272–273  
 distal/lateral subungual onychomycosis, 270  
 mid-plate onychomycosis, 272  
 proximal subungual onychomycosis, 270  
 relapse of onychomycosis, 273  
 total dystrophic onychomycosis, 272  
 white/black superficial onychomycosis, 271–272
- fungal infections of the scalp  
 piedra, 258–259  
 pityriasis amiantacea, 256  
 pityriasis capitis, 255–256  
 seborrheic dermatitis, 255–256  
 tinea capitis, 256–258
- fungating granulomas, 67
- fungi  
 dematiaceous fungi  
*Cladosporium carrionii*, 156  
*Fonsecaea compacta*, 156  
*Fonsecaea pedrosoi*, 156  
*Phialophora verrucosa*, 156  
*Rhinocladiella aquaspersa*, 98–99, 156  
 dimorphic fungi  
*Paracoccidioides brasiliensis*, 106–109, 158–159  
*Sporothrix schenckii*, 155, 155  
*Hortaea werneckii*, 154  
*Lacazia loboi*, 102, 157
- furuncles, 17. *See also* carbuncles  
 in diabetes mellitus, 248  
*S. aureus* as causative, 19  
 treatment, 20
- furunculosis  
 in athletes, 238–239  
 in elderly patients, 234–235  
 in mycobacterium fortuitum complex, 89
- Fusarium* spp., 113, 270, 271–272
- fusidic acid, for scalp cellulitis, 263
- gabapentin  
 for herpes zoster, 235  
 for post-herpetic neuralgia, 31
- Galen, on treatment of ulcerations, 59
- ganciclovir (oral), for CMV, 187, 202
- Gardnerella (Haemophilus) vaginalis*, 295
- genital bite wounds, 316–317
- genital herpes, 318–319  
 in AIDS patients, 186  
 from HSV-2, 27, 276
- genital ulcers, 3, 275
- genital warts (condyloma acuminatum), 203  
 clinical manifestations, 26  
 preventative therapies, 26  
 treatment, 26
- gentamicin antibiotic ointment, for Old World CL, 143–143
- Germ Theory paradigm, 275
- gingival stomatitis, 27
- gingivitis, acute necrotizing ulcerative, 294–295
- Glucantime® (meglumine antimonate), for Old World CL, 143
- glycopeptides, for cellulitis/erysipelas, 234
- gnathostomiasis, 126–127  
*Gnathostomiasis americanum*, 126  
*Gnathostomiasis binucleatum*, 126  
*Gnathostomiasis doloresi*, 126  
*Gnathostomiasis miyasaki*, 126  
*Gnathostomiasis procyonis*, 126  
*Gnathostomiasis spinigerum*, 126  
*Gnathostomiasis turgidum*, 126
- gonococcal infection, 3
- gonorrhea, 315–316  
 clinical presentation/diagnosis, 315–316, 320  
 epidemiology, 315  
 historical background, 310  
 with HIV, 284  
 treatment, 316
- gram-negative bacteria (in children)  
 cat-scratch disease, 215  
 ecthyma gangrenosum, 214–215  
 ehrlichiosis, 215
- gram-positive bacteria (in children)  
 blistering dactylitis, 212  
 ecthyma, 211  
 erysipeloid, 214  
 erythrasma, 214  
 impetigo, 211  
 necrotizing fasciitis, 213  
 orbital/periorbital cellulitis, 213  
 perianal streptococcal dermatitis, 212  
 pitted keratolysis, 214  
 scarlet fever, 212  
 trichomycosis axillaris, 214
- granuloma annulare, 78
- granuloma annulare vs. Hansen's disease lesions, 78
- granulomas  
 from *Aphrodite aculeata* ("sea mouse"), 176  
 candidal, 222  
 categories, 6  
 epithelioid, 74, 83  
 fungating, 67  
 lymphocytes in, 61  
 necrotizing, 141  
 pelvic/peritoneal, 128  
 pyogenic granulomata, 189, 197  
 from sea urchins, 173, 180  
 tuberculoid, 6, 7, 62, 70
- granulomatous diseases, 2  
 entomophthorales infections, 111  
 fish tank/swimming pool granulomas, 88, 178, 244  
 granuloma inguinale (donovanosis), 3, 6, 190–191  
 granulomatous dermatitis, 114  
 granulomatous meningo-encephalitis, 121  
 interstitial granulomatous dermatitis, 146–147  
 lethal midline granulomas, 122, 209, 287  
 lymphogranuloma venereum (LGV), 191  
 Majocchi's disease, 191, 234  
 mycetoma, 97–98  
 pbmycosis, 106  
 Wegner's granulomatosis, 164
- green foot, in athletes, 240
- griseofulvin (oral), 47  
 for tinea capitis, 51, 217, 258  
 for tinea imbricata (tokelau), 219
- group A  $\beta$ -hemolytic streptococci (GABHS)  
 blistering dactylitis from, 212  
 ecthyma from, 211  
 impetigo from, 211  
 perianal streptococcal dermatitis from, 212  
 scarlet fever from, 212
- gyrate erythema, 78
- H. capsulatum*, 7  
*Haemagogus*, 152  
*Haemophilus ducreyi*, 312, 313  
*Haemophilus influenzae*, 19, 213
- hair-cutting (treatment)  
 for black piedra, 154  
 for white piedra, 154
- HA-MRSA. *See* hospital associated methicillin resistant *Staphylococcus aureus*
- hand, foot, and mouth disease, 35–36, 283–284
- Hansen, Gerhard Henrik Armauer, 76
- Hansen's disease (leprosy). *See also* borderline lepromatous (BL) disease; borderline tuberculoid (BT) leprosy; lepromatous leprosy (LL)  
 clinical findings/classification criteria  
 Ridley-Jopling (classification), 78–80, 83  
 WHO (classification), 76, 80  
 epidemiology/microbiology/transmission, 76–77  
 historical background, 76  
 hypersensitivity reactions, 80–82  
 immunology/pathogenicity, 77  
 laboratory tests, 82–83  
 pathology, 83–84  
 pitfalls/myths about, 86–87  
 treatment/therapy, 84–86
- Haplochlora maculosa* octopus, 174



- helminths, 123–131  
 cestodes, 128–130  
   coenurosis, 129–130  
   cysticercosis, 129  
   echinococcosis, 129  
   sparganosis, 129  
 nematodes, 123–128  
   cutaneous larva migrans, 124–125  
   dracunculiasis, 124–125  
   enterobiasis, 128  
   filariasis, 123–124  
   gnathostomiasis, 126–127  
   loiasis, 124  
   mansonelliasis, 128  
   onchocerciasis, 124  
   trichinellosis, 127–128  
 trematodes, 130–131  
   fascioliasis, 130  
   paragonimiasis, 131  
   schistosomiasis, 130  
*b-hemolytic Group A streptococci*, 250  
 hemorrhagic fevers, 92, 151, 153. *See also*  
   South American hemorrhagic fevers  
 hepatitis A virus (HAV), 36  
 hepatitis B virus (HBV), 35  
   clinical manifestations, 35  
   diagnosis, 35  
   treatment, 35  
 hepatitis C virus (HCV), 37  
   clinical manifestations, 37  
   treatment, 37  
*Hermodice carunculata* polychaetes, 176  
 herpangina, 36, 276, 282–283  
 herpes labialis, 27, 240, 276  
 herpes simplex virus (HSV)  
   in athletes  
     activation, 240  
     skin-to-skin transmission, 240–241  
   chronic ulcerative, 30  
   generalized acute mucocutaneous, 30  
   in immunosuppressed patients, 29–30  
   in scalp infections, 264  
   systemic, 30  
 herpes simplex virus 1 (HSV-1)  
   clinical manifestations, 27  
   diagnosis, 27  
   in HIV infection, 186  
   in mucous membrane infections, 276–278  
   in transplantation recipients, 199–200  
   treatments, 29  
   viral properties, 27  
 herpes simplex virus 2 (HSV-2)  
   clinical manifestations, 29  
   in HIV infection, 186  
   in mucous membrane infections, 276–278  
   in transplantation recipients, 199–200  
   treatments, 29  
   viral properties, 29  
 herpes virus, various presentations of  
   chickenpox, 30  
   congenital HSV, 30  
   cytomegalovirus (HHV-5), 33  
   Epstein-Barr virus (HHV-4), 31–32  
   human herpes virus 7, 33  
   in-utero infections  
     congenital varicella syndrome, 30  
     infantile zoster, 31  
     neonatal varicella, 31  
   Kaposi sarcoma (HHV-8), 33–34  
   roseola infantum (HHV-6), 33  
   treatment, 30  
   varicella zoster (HHV-3), 30  
   zoster (shingles), 31–32  
 herpes virus B (herpes simiae), 34  
 herpes zoster virus (HSV), 3, 30, 207  
   in AIDS patients, 186  
   diagnosis, 31  
   in elderly patients, 235  
   pediatric manifestations  
     eczema herpeticum, 225–226  
     gingivostomatitis, 225  
     herpes gladiatorum, 226–227  
     herpetic whitlow, 226  
   in scalp infections, 264  
   treatment, 31  
   vaccination for, 31, 235  
 herpetic folliculitis, in AIDS patients, 186  
 herpetic whitlow, 186, 226  
 HHV 4. *See* Epstein-Barr virus (EBV)  
 HHV-8. *See* Kaposi's sarcoma (KS)  
 highly active antiretroviral therapy  
   (HAART)  
   causative for varicella zoster virus, 186  
   for folliculitis, 189  
   for HIV, 185, 310  
   for oral hairy leukoplakia, 187  
   for penicilliosis, 193  
 Hippocrates, 275  
 histoid leprosy, 80  
*Histoplasma*, 3  
*Histoplasma capsulatum*, 104  
 Histoplasmin test, 4  
 histoplasmosis, 104–105  
   diagnosis, 104  
   in HIV infection, 191–192  
   in mucous membrane infections,  
     288–289  
   oral itraconazole for, 47  
   treatment, 104–105  
   vs. molluscum contagiosum, 187  
 historical background  
   of AIDS, 185  
   of arthropod-borne infections, 92–93  
   of athlete skin infections, 238  
   of atypical mycobacterioses, 88  
   of bacterial/viral disease in transplant  
     recipients, 195  
   of cancer patients and skin infections,  
     206  
   of common bacterial infections, 18–19  
   of common fungal infections, 42  
   of cutaneous tuberculosis, 59  
   of HIV-related skin infections, 185  
   of Kaposi sarcoma, 185  
   of life-threatening skin infections, 322  
   management principles, 8  
   of mucous membrane infections, 275  
   of Old World cutaneous leishmaniasis,  
     135  
   of parasitology, 117  
   of pediatric skin infections, 211  
   of sexually transmitted diseases, 309–310  
   of skin surgery-related infections, 303  
*History of Animals* (Aristotle), 117  
 HIV-related skin infections. *See also* sexually  
   transmitted diseases (STDs) and HIV  
   skin infections  
 acute exanthem  
   cytomegalovirus, 187  
   Epstein-Barr virus, 187  
   herpes simplex virus (types 1  
     and 2), 186  
   human herpes virus 8, 188–189  
   pox virus, 187  
   varicella-zoster virus, 186–187  
 bacterial infections  
   bacillary angiomatosis, 189–190  
   folliculitis, 189  
   impetigo, abscesses, cellulitis,  
     necrotizing fasciitis, 189  
   mycobacterial infections, 189  
 co-infections  
   cutaneous lesions of histoplasmosis,  
     104  
   cutaneous tuberculosis, 59, 72  
   with *Mycobacterium leprae*, 83  
 diagnosis, 38  
 fungal infections  
   aspergillosis, 192  
   blastomycosis/sporotrichosis, 193  
   candidiasis, 191  
   coccidiomycosis, 192  
   cryptococcus, 191  
   dermatophytosis, 191  
   histoplasmosis, 191–192  
   paracoccidiomycosis, 192  
   penicilliosis, 192–193  
   pneumocystosis, 191  
 historical background, 185  
 mucous membrane infections, 284  
 parasitic/ectoparasitic infections  
   acanthamebiasis, 193–194  
   demodicidosis, 193  
   leishmaniasis, 194  
   scabies, 193  
 from sexually transmitted diseases  
   (STDs)  
   granuloma inguinale (donovanosis),  
     190–191  
   lymphogranuloma venereum (LGV),  
     191  
   syphilis, 190  
 HLA-DQ1 association with lepromatous  
   leprosy, 77  
 Horta, Parreiras, 151  
*Hortaea werneckii* fungus, 154  
 hospital associated methicillin resistant  
   *Staphylococcus aureus*  
   (HA-MRSA), 19  
 hospital gangrene. *See* necrotizing fasciitis  
 hot-tub folliculitis, 19, 20, 240, 261  
 human African trypanosomiasis (sleeping  
   sickness), 122–123  
 human granulocytic anaplasmosis (HGA),  
   215

## 338 — Index

- human herpes virus 3 (HHV-3). *See* varicella zoster virus
- human herpes virus 4 (HHV-4). *See* Epstein-Barr virus
- human herpes virus 5 (HHV-5). *See* cytomegalovirus
- human herpes virus 6 (HHV-6). *See* roseola infantum
- human herpes virus 7 (HHV-7), 33
- human herpes virus 8 (HHV-8). *See* Kaposi's sarcoma
- human monocytic ehrlichiosis (HME), 215
- human papillomavirus (HPV)
- anogenital disease
    - bowenoid papulosis, 26
    - condyloma acuminatum, 26, 188
    - verruca carcinoma, 26–27
  - in HIV infection, 187–188
  - low risk/high risk subtypes, 188
  - in mucous membrane infections, 280–281
  - nongenital cutaneous diseases
    - Butcher's warts, 26
    - common warts (*verruca vulgaris*), 25
    - epidermodysplasia verruciformis (EV), 25–26
    - flat warts (*verrucae plana*), 25
    - palmoplantar warts (*myrmecia*), 25
  - nongenital mucosal disease
    - oral focal hyperplasia (Heck disease), 27
  - in transplantation recipients, 203
- Hutchinson, Jonathan, 59
- hyalohyphomycosis, 113–114
- causative agents, 113
  - treatment, 113–114
- hydroids, reactions to, 172
- hyperbaric oxygenation, 9
- hyperglycemia control for diabetes skin infections, 249, 251, 252
- hyper-IgE syndrome, 222
- hyperimmune globulin, for South American hemorrhagic fevers, 153
- IgG immunoglobulin, 9
- IL-8 cytokine association with lepromatous leprosy, 77
- IL-12 cytokine association with lepromatous leprosy, 77
- imidazoles
  - for localized *Candida*, 286
  - for *pedra*, 259
- imipenem, for nocardiosis, 198
- imiquimod (topical)
  - for condyloma acuminatum, 188
  - for molluscum contagiosum, 187
  - for Old World CL, 144
  - for *verrucae vulgaris*/condyloma acuminatum, 203
- immune reconstitution inflammatory syndrome (IRIS), 186
- immunoglobulin (IV)
  - for staphylococcal TSS, 325
  - for streptococcal TSS, 326
- impetigo, 18
- in athletes, 238
  - in children, 211
  - diagnosis, 20
  - in elderly patients, 234–235
  - in HIV, 189
  - S. aureus*/*S. pyogenes* causative for, 19
  - in scalp infections, 261–262
  - treatment, 20
- In Situ Hybridization (ISH), 5
- Indians, and lepromatous leprosy, 77
- Indo-Aryans, 59
- induration (as sign of acute infection), 8
- infections diseases, diagnostic techniques
  - culture, 3
  - intralesional reactions, 3–4
  - molecular biology, 5–6
  - sample collection, 2
  - serology, 4–5
  - skin biopsy, 6–7
  - smears, 2–3
- infestations of children, 230–232
- bedbugs, 232
  - blister beetles, 232
  - caterpillars and moths, 232
  - fleas, 231–232
  - mites, 230–231
  - papular urticaria, 231
  - pediculosis, 230
  - scorpions, 231
  - spiders, 231
  - stinging insects, 232
- insect repellants. *See* DEET (N,N-diethyl-3-methylbenzamide) mosquito repellent
- interferon  $\alpha$ 
  - for condyloma acuminatum, 188
  - for hepatitis B, 35
  - for KS, 34
- interstitial granulomatous dermatitis, 146–147
- intralesional reactions, 3–4
- intraepidermal abscesses (in chromomycosis), 99
- intralesional interferon
  - for KS, 280
  - for *verrucae vulgaris*/condyloma acuminatum, 203
- intralesional vinblastine, for KS, 34, 280
- in-utero herpes infections
  - congenital varicella syndrome, 30
  - infantile zoster, 31
  - neonatal varicella, 31
- isoniazid
  - for cutaneous TB treatment, 73
  - for pulmonary tuberculosis, 292
- isotretinoin
  - for erosive pustular dermatosis of scalp, 263
  - for scalp cellulitis, 263
- Ito Reenstierna test, 4
- itraconazole
  - for candidiasis, 191
  - for coccidioidomycosis, 192
  - for cutaneous cryptococcus, 191
  - for entomophthoromycosis, 111
  - for histoplasmosis, 192
  - for hyalohyphomycosis, 113
  - for lobomycosis, 158
  - for mycetoma, 157
  - for Old World CL, 143
  - for onychomycosis, 191
  - for paracoccidioidomycosis, 109, 159
  - for protothecosis, 175
  - for tinea capitis, 217, 258
- itraconazole (oral), 47
- adverse effects, 47
  - for North American blastomycosis, 105–106
  - for penicilliosis, 193
  - for pityriasis versicolor, 53
  - for sporotrichosis, 102
  - for tinea capitis, 51, 51
  - for tinea corporis/cruris/faciei, 50–51
  - for tinea pedis/manuum, 47–50
  - for tinea unguium (onychomycosis), 52, 236
  - for toenail onychomycosis, 52
- itraconazole (topical), for tinea nigra, 154–155
- ivermectin
  - for demodicidosis, 260
  - with doxycycline for onchocerciasis, 124
  - for filariasis, 124
  - for gnathostomiasis, 127
  - for loiasis, 124
  - for mansonelliasis, 128
  - for onchocerciasis, 124
  - for onchocercosis, 176
  - for scabies, 193, 260, 317–318
- Ixodes pacificus*, 215
- Ixodes scapularis*, 215
- jellyfish, reactions to, 168–169
- Jones, Joseph, 8
- Jorge Lobo's disease. *See* keloidal blastomycosis
- K. rhinoscleromatis*, 7, 7
- Kaposi's sarcoma (KS), 5, 33–34
- clinical manifestations, 33
  - diagnosis, 34
  - historical background, 185
  - in HIV infection, 188–189
  - in mucous membrane infections, 280
  - in transplantation recipients, 202
  - treatment, 34
- Katayama syndrome, 130
- keloidal blastomycosis, 102, 157
- ketoconazole
  - for entomophthoromycosis, 111
  - for Old World CL, 143
  - for paracoccidioidomycosis, 109
  - for pityriasis versicolor, 53
  - for tinea capitis, 51, 258
  - for tinea corporis/cruris/faciei, 50
  - for tinea pedis/manuum, 47
- ketoconazole (oral), 47
- adverse effects, 47
  - for dermatophyte fungal infections, 248
  - for North American blastomycosis, 105–106
  - for pityriasis versicolor, 53
  - for protothecosis, 175

- ketoconazole (shampoo), 256  
 for tinea capitis, 217, 218  
 for tinea corporis gladiatorum, 244  
 ketoconazole (topical)  
 for tinea nigra, 154–155  
 for tinea pedis/manuum, 47–50, 236  
 for white piedra, 154  
*Klebsiella pneumoniae*, 19  
 Koch, Robert, 59  
 KOH preparations, 2–3
- L. loboi* (lobomycosis), 3, 7  
*Lacazia loboi* fungus, 102, 157  
 Laennec, Rene, 59  
 larva currens, 126  
 larva migrans cutanea, 176–177  
 laser treatment  
 for Bowenoid papulosis, 26  
 for condyloma acuminata, 188  
 for folliculitis keloidalis, 262  
 for oral florid papillomatosis, 281  
 for pseudofolliculitis barbae, 216  
 for rhinoscleroma, 294  
 for verrucae vulgaris/condyloma acuminatum, 203, 228
- Lassa fever, 153  
*Latruncula magnifica* red sponge, 174  
 Laws of Manu, 59  
 Leão, Arêa, 151  
 leeches, reactions to, 176  
*Legionella*, 4  
 Leishman, W. B., 135  
*Leishmania aethiopica*, 117–118  
*Leishmania amazonensis*, 119, 161  
*Leishmania braziliensis (viannia)*, 117, 120, 150, 160–161  
*Leishmania chagasi*, 119  
*Leishmania donovani*, 117, 119  
*Leishmania guyanensis*, 161  
*Leishmania infantum*, 117–118, 119  
*Leishmania major*, 117–118  
*Leishmania mexicana*, 117  
*Leishmania panamensis*, 120  
*Leishmania peruviana*, 117  
*Leishmania tropica*, 117  
 leishmaniasis, 92, 117–121. *See also* anergic leishmaniasis; mucocutaneous/tegumental leishmaniasis; Old World cutaneous leishmaniasis  
 classifications  
 cutaneous leishmaniasis, 117  
 diffuse cutaneous, 4  
 lupus leishmaniasis, 74  
 mucocutaneous leishmaniasis, 119  
 new world leishmaniasis, 118–121  
 old World leishmaniasis, 117–118  
 clinical manifestations, 161, 296  
 diagnosis, 120  
 in HIV infection, 194  
 in Texas, borne by sandflies, 92  
 treatment, 120–121  
 vacuolated histiocytes with lymphoplasmacytic infiltrate in, 6  
 visceral, 4
- Leishmanin test (Montenegro test), 4  
 lepromatous leprosy (LL), 4, 7, 77, 79  
 histopathology, 83  
 HLA-DQ1 association, 77  
 Lucio's phenomenon in, 82  
 oral lesions in, 292  
 resemblance to disseminated coccidioidomycosis, 147  
 Lepromin test, 4  
 leprosy. *See* Hansen's disease  
*Leptospira*, 4  
 Letterer-Siwe syndrome, 74  
 lichen scrofulosorum (LS), 68–69, 75  
 lidocaine (topical)  
 for herpes zoster, 235  
 for HSV, 277  
 for oral infections, 275, 277  
 for post-herpetic neuralgia, 31  
 life-threatening skin infections  
 historical background, 322  
 meningococcal disease, 322–323  
 Rocky Mountain spotted fever, 92, 323–324  
 staphylococcal toxic shock syndrome, 324–325  
 streptococcal toxic shock syndrome, 325–327  
 ligase based method (of PCR), 5  
 lindane  
 for demodicidosis, 260  
 for pediculosis capitis, 259  
 for scabies, 260  
 topical, for scabies, 317–318  
 linear streaking along lymphatics (as sign of acute infection), 8  
 linezolid  
 for impetigo/folliculitis/furunculosis, 235–234  
 for MRSA strains, 20  
 for nocardiosis, 198  
 for *S. aureus*, 196  
*Linuche unguiculata* jellyfish, 171–172  
*Loa loa*, 124  
 Lobo, Jorge, 102, 151  
 lobomycosis, 102–103, 151  
 diagnosis, 103  
 treatment, 103  
 loiasis, 124  
 lower extremity cellulitis, pitfalls and myths, 21  
 Lucio's phenomenon, 82, 84, 85  
 lupoid rosacea, 74  
 lupus leishmaniasis, 74  
 lupus vulgaris, 59, 62–64, 74, 78  
 Lutz, Adolpho, 151  
*Lutzomyia* genera, 117  
 Lyme disease, 92, 95, 215  
 lymphadenopathy (as sign of acute infection), 8  
 lymphogranuloma venereum (LGV), 309, 313–314  
*Lyngbya majuscola* seaweed, 174
- macrolides  
 for atypical mycobacterioses, 90  
 for *Balamuthia mandrillaris*, 122  
 for perianal streptococcal dermatitis, 212  
*Madurella mycetomatis* grains, 156  
 Majocchi's granuloma, 191  
 malaria, 92, 93, 95, 150  
*Malassezia globosa* yeast, 256  
*Malassezia restricta* yeast, 256  
 malathion  
 for pediculosis capitis, 259  
 for public lice, 318  
 malignant otitis externa, 251  
 malignant skin infections  
 angiosarcoma, 209  
 breast cancer, inflammatory, 208–209  
 cancers metastatic to skin, 210  
 keratoacanthoma, 209–210  
 lethal midline granuloma, 209  
 leukemia cutis, 208  
 lymphoma, 208  
 squamous cell cancer, 209  
 Stewart-Treves syndrome, 209  
 verrucous carcinoma, 209  
 management principles  
 clinical diagnosis, 8  
 historical background, 8  
 laboratory diagnosis, 8  
 myths/pitfalls, 9–13  
 treatment, 8–9  
*Mansonella ozzardi*, 128  
*Mansonella perstans*, 128  
*Mansonella streptocerca*, 128  
 mansonelliasis, 128  
 Mantoux test, 4  
 maprotiline, for post-herpetic neuralgia, 31  
 Marburg/Ebola virus, 153  
 Masters of the Salerno School of Medicine, 59  
*Mastomys natalensis* rodent, 153  
 measles/rubeola, 36–37  
 clinical manifestations, 36  
 diagnosis, 37  
 in mucous membrane infections, 283  
 ProQuad vaccine for, 278  
 treatment, 37  
 mebendazole  
 for dracunculiasis, 125  
 for enterobiasis, 128  
 for trichinellosis, 128  
 melarsoprol, for trypanosomiasis, 123  
 Meleney's ulcer, 8  
 meningococcal conjugate vaccine A, C, Y, W-135, 323  
 meningococcal disease  
 clinical manifestations, 322–323  
 diagnosis, 323  
 management, 323  
 pitfalls and myths, 327  
 meningoencephalitis, 152, 152  
 methicillin, introduction of, 19  
 methicillin resistant *Staphylococcus aureus* (MRSA), 19, 20, 189, 195, 238, 262  
 methicillin sensitive *Staphylococcus aureus* (MSSA), 19, 195  
 N-methylglucamine, for leishmaniasis, 164

## 340 — Index

- methylprednisolone, for post-herpetic neuralgia, 31
- metronidazole  
 for acute necrotizing ulcerative gingivitis, 295  
 for bacterial vaginosis, 295  
 for demodicidosis, 260  
 for dracunculiasis, 125  
 IV/oral, for enteric amebiasis, 121  
 for noma, 295  
 for trichomoniasis, 296
- miconazole  
 for erythrasma, 249  
 for hyalohyphomycosis, 113  
 for pityriasis versicolor, 53  
 for tinea corporis/cruris/faciei, 50  
 for tinea pedis/manuum, 47  
 topical, for tinea nigra, 154–155
- miconazole nitrate 1%, for tinea pedis/manuum, 47
- microbial paronychia infections, 268
- Microciona prolifera* sponge, 174
- Micrococcus (Kytococcus) sedentarius*, 214
- Micrococcus* spp., 189
- Microsporium audouinii*, 256
- Microsporium canis*, 256
- Microsporium distortum*, 256
- mid-plate onychomycosis, 272
- Miller's nodules (Paravaccinia)  
 clinical manifestations, 24  
 diagnosis, 24  
 treatment, 24
- miltefosine, for Old World CL, 144
- minocycline. *See also* ROM therapy  
 for atypical mycobacteria, 244  
 for *Mycobacterium marinum*, 179  
 for nocardiosis, 198
- Mitsuda lepromin antigen, 4
- MMR (measles, mumps, rubella)  
 vaccination, 283
- Moh's surgery, 303, 305
- molecular biology, 5–6
- molluscum contagiosum virus (MCV), 7, 23  
 in athletes, 241–242  
 in children, 228–229  
 clinical manifestations, 23  
 in HIV infection, 187  
 in mucous membrane infections, 281  
 in transplant recipients, 202–203  
 treatment, 23
- mollusks and aquatic dermatoses, 174
- monkeypox, in children, 229
- Montenegro, João, 151
- Montenegro test (Leishmanin test), 4
- Mosquito Magnet (mosquito trap), 95
- mosquito vectors  
 of Barmah Forest virus, 153  
 of mucocutaneous/tegumental leishmaniasis, 161  
 of West Nile virus, 152  
 of Yellow fever, 152
- moths and caterpillars, 232
- mouse-borne diseases, 92
- mouth rinses with topical anesthetic agents, for HSV 1/2 infections, 277
- MRSA. *See* methicillin resistant *Staphylococcus aureus*
- mucocutaneous/tegumental leishmaniasis, 160–164  
 clinical manifestations, 161–164  
 diagnosis, 164  
 mosquito vectors, 161  
 transmission, 161  
 treatment, 164
- Mucorales (Zygomycosis)*, 109
- mucormycosis, 7, 109–110. *See also* rhinocerebral mucormycosis  
 clinical patterns, 109, 287  
 diagnosis, 287  
 treatment, 110, 287
- mucous membrane infections  
 bacterial infections, other  
 actinomycosis, 294  
 acute necrotizing ulcerative gingivitis, 294–295  
 anthrax, 295  
 bacterial vaginosis, 295  
 diphtheria, 293–294  
 mycoplasma pneumoniae, 296  
 noma (cancrum oris/gangrenous stomatitis), 295  
 pseudomonas aeruginosa, 295  
 rhinoscleroma, 294  
 staphylococcus, 293  
 streptococcus, 293  
 tetanus, 296
- DNA viruses  
 Epstein-Barr virus, 278–279  
 human papilloma virus, 280–281  
 human simplex 1 and 2, 276–278  
 Kaposi's sarcoma, 280  
 molluscum contagiosum, 281  
 parvovirus B19, 281  
 roseola infantum, 279–280  
 varicella zoster, 278
- fungal infections  
 chronic mucocutaneous candidiasis, 286  
 endemic mycoses, 288–290  
 blastomycosis, 289  
 coccidioidomycosis, 289–290  
 histoplasmosis, 288–289  
 paracoccidioidomycosis, 289  
 nonendemic mycoses, 286–288  
 aspergillosis, 288  
 disseminated candidiasis, 286  
 mucormycosis, 286–287  
 superficial mycoses/*Candida* spp., 284–286
- historical background, 275
- mycobacterial infections  
 leprosy, 292–293  
 mycobacterium avium intracellulare, 292  
 tuberculosis, 292
- protozoa  
 leishmaniasis, 296–297  
 trichomoniasis, 296
- RNA retroviruses, 284  
 HIV, 284  
 human T-lymphotropic virus, 284
- RNA viruses, 281–284  
 hand-foot-and-mouth disease, 281–282  
 herpangina, 282–283  
 measles, 283  
 mumps, 283  
 rubella, 283–284
- sexually transmitted bacterial infections  
 spirochetes, 291  
 syphilis, 291–292
- mumps  
 in mucous membrane infections, 283  
 ProQuad vaccine for, 278
- mupirocin (topical)  
 for folliculitis, 20, 239  
 for impetigo, 20, 211  
 for nasal carriage, 21  
 for *S. aureus* in transplant recipients, 196
- mycetoma, 97–98, 156–157
- Mycobacterium abscessus*, 3
- Mycobacterium africanum*, 60
- Mycobacterium avium* complex, 89, 292
- Mycobacterium avium-intracellulare*  
 lymphadenitis, 64, 74
- Mycobacterium bovis*, 60, 64. *See also* scrofuloderma
- Mycobacterium chelonae*, 3
- Mycobacterium chelonae-Mycobacterium abscessus* complex, 89
- Mycobacterium fortuitum*, 3
- Mycobacterium fortuitum* complex, 89
- Mycobacterium kansasii*, 4, 88
- Mycobacterium leprae*, 3, 4, 5, 7, 60, 76, 292–293. *See also* Hansen's disease
- Mycobacterium marinum*, 7, 67, 88, 173, 178–179
- Mycobacterium microti*, 60
- Mycobacterium scrofulaceum*, 4, 64, 74, 89
- Mycobacterium tuberculosis*, 3, 4, 6, 7, 60, 61.  
*See also* cutaneous tuberculosis  
 causative for tuberculosis, 292  
 classification, 62  
 diagnosis, 61–62  
 histopathology, 70–71  
 HIV and, 72  
 PCR for, 189
- Mycobacterium ulcerans*, 3–5, 7
- mycoplasma pneumoniae, 296
- Mycosel anaerobes, 3
- Naegleria* spp., 121
- naftifine hydrochloride 1%, for tinea pedis/manuum, 47
- nail unit infections  
 fungal infections, 269–273  
 combined variants of onychomycosis, 272–273  
 distal/lateral subungual onychomycosis, 270

- mid-plate onychomycosis, 272  
 proximal subungual onychomycosis, 270  
 relapse of onychomycosis, 273  
 total dystrophic onychomycosis, 272  
 white/black superficial onychomycosis, 271–272  
 historical background, 268  
 paronychia infections  
 acute, 268–269  
 chronic, 269  
 microbial, 268  
 pitfalls and myths, 273  
 structure of nail unit, 268  
 necrosis (as sign of acute infection), 8  
 necrosis lipoidica vs. Hansen's disease lesions, 78  
 necrotizing fasciitis, 8  
 in children, 213  
 in diabetes mellitus, 250  
 differentiation of via creatinine phosphokinase, 8  
 in elderly patients, 235  
 in HIV, 189  
 HIV infection and, 189  
 medication for  
 cefoperazone sodium, 213  
 clindamycin for, 213  
 creatinine phosphokinase, 213  
 in transplant recipients, 197  
*Neisseria gonorrhoeae*, 2, 315, 316  
*Neisseria meningitidis*, 4, 322, 322  
 nematocysts of coelenterates, 168  
 nematodes, 123–128  
 and aquatic dermatoses, 176–177  
 cutaneous larva migrans, 124–125  
 dracunculiasis, 124–125  
 enterobiasis, 128  
 filariasis, 123–124  
 gnathostomiasis, 126–127  
 loiasis, 124  
 mansonelliasis, 128  
 onchocerciasis, 124  
 trichinellosis, 127–128  
 new world leishmaniasis, 118–121  
 nifurtimox  
 for American trypanosomiasis, 123  
 for Chagas' disease, 160  
 N-methylglucamine, for leishmaniasis, 164  
 nocardia, 2, 198, 264  
*Nocardia asteroides*, 198  
*Nocardia brasiliensis*, 97, 156  
 nocturnal pruritus, 260  
 noma (cancrum oris/gangrenous stomatitis), 295  
 non-bullous impetigo, 211  
 nongenital cutaneous diseases  
 Butcher's warts, 26  
 common warts (verruca vulgaris), 25  
 epidermodysplasia verruciformis (EV), 25–26  
 flat warts (verrucae plana), 25  
 palmoplantar warts (myrmecia), 25  
 nonsteroidal anti-inflammatory drugs (NSAIDs)  
 association with gangrene, 8  
 for ENL treatment, 84  
 for HSV 1 and 2 infections, 277  
 for HSV infection, 277  
 for multibacillary/paucibacillary disease, 84  
 North American blastomycosis, 6, 105–106  
 diagnosis, 105  
 treatment, 105–106  
 Nucleic Acid Sequence-based Amplification (NASBA), 5  
 nucleoside reverse transcriptase inhibitors (NRTIs), 38  
*Occult amigdalitis paracoccidiosa*, 107  
*Ochlerotatus* mosquito, 152, 153  
*Octopus vulgaris*, 174  
 olamine (topical)  
 for tinea pedis/manuum, 47  
 for white piedra, 154  
 Old World cutaneous leishmaniasis (CL), 117–118  
 clinical presentation, 138–140  
 diagnosis, 140–141  
 epidemiology, 135–136  
 historical background, 135  
 patient follow-up, 144  
 prevention, 137–138  
 transmission: sandfly vector/*Leishmania* lifecycle, 136–137  
 treatment, 141–144  
 Onchocerca skin test, 4  
*Onchocerca volvulus*, 124, 175  
 onchocerciasis, 123, 124, 175–176  
 onychomycosis. *See also* tinea unguium  
 dermatophyte onychomycosis, 47, 52  
 distal subungual onychomycosis, 236  
 distal/lateral subungual, 270  
 mid-plate, 272  
 proximal subungual, 270  
 relapse of, 273  
 total dystrophic, 272  
 white/black superficial, 271–272  
 opiates, for herpes zoster, 235  
 oral hairy leukoplakia (OHL), 187  
 orbital cellulitis, 213, 287  
 orf virus, 81.10  
 organomegaly, 130  
 orificial tuberculosis, 67–68, 74–75  
 oropharyngeal candida (thrush), 221  
 oropharyngeal/esophageal candidiasis, 47  
 otitis externa (malignant), 246, 251–252  
 oxygen therapy, for Dengue fever, 152  
*P. braziliensis* (South American blastomycosis). *See* paracoccidioidomycosis  
*Paecilomyces* spp., 113  
 PAIR ((percutaneous aspiration, infusion of scolicidal agents, respiration)) procedure, 129  
 palmoplantar warts (myrmecia), 25  
*Panstrongylus megistus* parasite, 160  
 papular urticaria, 231  
 papulonecrotic tuberculids, 68, 75  
*Paracentrotus lividus* sea anemone, 172  
 paracoccidioidomycosis (South American blastomycosis), 6, 106–109, 158–159  
 acute/subacute form (childhood/juvenile type), 106–107  
 chronic form (adult type), 107–108  
 clinical manifestations, 106, 158  
 diagnosis, 108, 158–159  
 discovery of, 151  
 in HIV infection, 192  
 in mucous membrane infections, 289–290  
 residual/sequel form, 108–109  
 treatment, 108–109, 159  
 paragonimiasis, 131. *See also* extrapulmonary paragonimiasis; scrotal paragonimiasis  
*Paragonimiasis westermani*, 131  
*Paramyxoviridae* virus, 153  
 parasitic infections of the scalp  
 demodicidosis, 260  
 pediculosis capitis, 259–260  
 scabies, 260  
 parasitology  
 helminths, 123–131  
 cestodes, 128–130  
 nematodes, 123–128  
 trematodes, 130–131  
 historical background, 117  
 pitfalls and myths, 131  
 protozoa  
 enteric amebiasis, 121  
 free living amebas, 121–122  
 leishmaniasis, 117 (*see also* leishmaniasis)  
 trypanosomiasis, 122–123  
 parenteral penicillin, for congenital syphilis, 223  
 Parinaud's oculoglandular syndrome, 215  
 PARK2 promoter region, association with Hansen's disease, 77  
 paromomycin (topical), for Old World CL, 143  
 paronychia infections of the nail unit  
 acute, 268–269  
 chronic, 269  
 microbial, 268  
 parvovirus B19, 35  
 clinical manifestations, 34  
 diagnosis, 35  
 in mucous membrane infections, 281  
 treatment, 35  
 paucibacillary disease treatment guidelines (WHO), 84  
 pbmycosis. *See* paracoccidioidomycosis (South American blastomycosis)  
 PCR. *See* polymerase chain reaction (PCR)  
 pediatric infestations, 230–232  
 bedbugs, 232  
 blister beetles, 232  
 caterpillars and moths, 232

## 342 — Index

- pediatric infestations (cont.)  
 fleas, 231–232  
 mites, 230–231  
 papular urticaria, 231  
 pediculosis, 230  
 scorpions, 231  
 spiders, 231  
 stinging insects, 232
- pediatric periorbital cellulitis, 19
- pediatric skin infections  
 clinical infections  
 angular cheilitis (perleche), 221  
 chronic mucocutaneous candidiasis (CMC), 221–222  
 chronic paronychia, 221  
 congenital candidiasis, 221  
 diaper dermatitis (monilial diaper dermatitis), 221  
 invasive fungal dermatitis, 221  
 oropharyngeal candida (thrush), 221  
 spontaneous intestinal perforation, 221  
 systemic candidiasis, 221  
 congenital infections, 222–225  
 cytomegalovirus, 224  
 neonatal HSV, 225  
 parvovirus B19, 225  
 rubella, 223–224  
 syphilis, 222–223  
 varicella zoster, 225
- eosinophilic pustula folliculitis, 216
- fungal infections, 216–221  
 dermatophytes  
 candidiasis, 220–221  
 piedra, 220  
 tinea capitis, 217–218  
 tinea cruris, 218  
 tinea faciei, 218  
 tinea imbricata (tokelau), 219  
 tinea incognito, 218  
 tinea nigra, 220  
 tinea unguium (onychomycosis), 218–219
- gram-negative bacteria, 214–215  
 cat-scratch disease, 215  
 ecthyma gangrenosum, 214–215  
 ehrlichiosis, 215
- gram-positive bacteria, 211–214  
 blistering dactylitis, 212  
 ecthyma, 211  
 erysipeloid, 214  
 erythrasma, 214  
 impetigo, 211  
 necrotizing fasciitis, 213  
 orbital/periorbital cellulitis, 213  
 perianal streptococcal dermatitis, 212  
 pitted keratolysis, 214  
 scarlet fever, 212  
 trichomycosis axillaris, 214
- historical background, 211
- infestations, 230–232  
 bedbugs, 232  
 blister beetles, 232  
 caterpillars and moths, 232  
 fleas, 231–232  
 mites, 230–231
- papular urticaria, 231
- pediculosis, 230
- scorpions, 231
- spiders, 231
- stinging insects, 232
- pseudofolliculitis barbae, 216
- spirochetes, 215–216  
 endemic treponematoses, 215–216  
 Lyme disease, 215
- viral diseases  
 HSV manifestations  
 eczema herpeticum, 225–226  
 gingivostomatitis, 225  
 herpes gladiatorum, 226–227  
 herpetic whitlow, 226  
 molluscum and poxviridae, 228–229  
 monkeypox, 229  
 vaccinia and variola, 229–230  
 verruca, 227–228
- pediatric streptococcal dermatitis, 212
- pediculosis, 154, 230
- pediculosis capitis (of the scalp), 259–260
- Pediculosis humanus capitis* parasite, 259
- pediculosis pubis, 318
- Pedroso and Lane's mycosis. *See*  
 chromoblastomycosis
- peginterferon  $\alpha$  for hepatitis C virus, 37
- pegylated interferon + ribavirin for hepatitis C virus, 37
- Pelagia noctiluca* jellyfish, 168
- Pelodera strongyloides*, 125
- peniclovir, for herpes labialis, 277
- penicillin  
 for actinomycosis, 294  
 for acute necrotizing ulcerative gingivitis, 295  
 for anthrax, 295  
 anti-pseudomonal, for ecthyma gangrenosum, 215  
 for cellulitis/erysipelas, 234  
 for erysipeloid, 214  
 for folliculitis keloidalis, 262  
 for impetigo/folliculitis/furunculosis, 235–234  
 introduction of, 18  
 with metronidazole  
 for Fournier's gangrene, 252  
 for necrotizing fasciitis, 252  
 for noma, 295  
 for perianal streptococcal dermatitis, 212  
 for *S. pyogenes* caused erysipelas, 20  
 for scarlet fever, 212  
 for streptococcal pharyngitis, 293
- penicillin G, for syphilis, 223, 312
- penicilliosis, in HIV infection, 192–193
- Penicillium marneffeii* infection, 187
- Penicillium* spp., 113, 187
- pentamidine  
 for *Balamuthia mandrillaris*, 122  
 for enteric amebiasis, 121  
 for trypanosomiasis, 123
- pentavalent antimonials, for leishmaniasis, 164, 297
- Pentostam® (sodium stibogluconate), for Old World CL, 121, 143, 164
- pentoxifylline, for ENL treatment, 84
- perianal streptococcal dermatitis, in children, 212
- periorbital cellulitis, in children, 213
- peripheral neuropathies, from Hansen's disease, 76
- perleche (angular cheilitis), 221
- permethrin (topical)  
 for demodicidosis, 260  
 for pediculosis capitis, 259  
 for public lice, 318  
 for scabies, 193, 260
- phaeohyphomycosis, 112–113
- Phialophora verrucosa*, 98–99, 113, 156
- phlebotominae insects (vectors), 161
- Phlebotomus papatasi*, 136
- Phlebotomus* sandfly, 117, 136–137.  
*See also* Old World cutaneous leishmaniasis (CL)
- Phlebotomus sergenti*, 136
- photodynamic therapy, for Old World CL, 144
- Physalia physalis* physaliae (Portuguese man-of-war), 172
- Physalia utriculus* physaliae, 172
- physaliae, reactions to, 172
- picornaviruses  
 Enteroviruses  
 hand, foot, and mouth disease, 35–36  
 hepatovirus: hepatitis A, 36  
 herpangina, 36
- Piedra hortae*, 258
- piedra nigra, 151, 220
- Piedraia hortai*, 151
- pilocarpine preparations  
 for leprosy diagnosis, 79  
 for pubic lice, 318
- Pirquet test, 4
- pitfalls and myths  
 of arthropod-borne infections, 95  
 of athletic skin infections, 244  
 of atypical mycobacterioses, 90–91  
 of cancer-related skin infections, 208  
 of common fungal infections, 53  
 of cutaneous tuberculosis, 73–75  
 of deep fungal infections, 114–116  
 of diabetic skin infections, 251  
 of elderly patient skin infections, 237  
 of erysipelas, 21  
 of folliculitis, 21  
 of Hansen's disease, 86–87  
 of HIV-related skin infections, 90–91  
 of lower extremity cellulitis, 21  
 of marine biotic agents, 179–181  
 of meningococcal disease, 327  
 of mucous membrane infections, 297  
 of nail unit infections, 273  
 of parasitology, 131  
 of pediatric skin infections, 232  
 of Rocky Mountain spotted fever, 327  
 of scalp infections, 264–265  
 of sexually transmitted disease, 319–320  
 of skin infections, 9–13  
 of staphylococcal toxic shock syndrome, 327

- of surgical skin infections, 306–307
- of tropical infections, 164–165
- of viral skin infections, 38
- pitted keratolysis
  - in athletes, 239–240
  - in children, 214
- pityriasis amiantacea (of the scalp), 256
- pityriasis capitis (of the scalp), 255–256
- pityriasis lichenoides et varioliformis acuta (PLEVA), 74
- pityriasis versicolor (PV), antifungal medications for, 52–53
- PLEVA. *See* pityriasis lichenoides et varioliformis acuta (PLEVA)
- Pliny the Elder, on tuberculosis, 59
- Pneumocystis carinii* pneumonia, 185
- pneumocystosis
  - cutaneous, 187
  - in HIV infection, 191
- podophyllin (topical)
  - for molluscum contagiosum, 187
  - for oral hairy leukoplakia, 187
- podophyllotoxin solution (or resin) for anogenital warts, 319
  - for condyloma acuminata, 188
  - for oral florid papillomatosis, 281
  - for oral hairy leukoplakia, 279
  - for verrucae vulgaris/condyloma acuminatum, 203
- polychaetes, dermatitis from, 176
- polymerase chain reaction (PCR), 5, 7, 38
- posaconazole, 110, 287
- potassium iodide (KI)
  - for entomophthoromycosis, 111
  - for sporotrichosis, 102
- povidone iodine shampoo, for tinea capitis, 51
- pox viruses
  - Molluscum Contagiosum* (MCV), 23
  - orthopox
    - cowpox, 24
    - monkey pox, 24
    - smallpox, 23
    - vaccinia, 24
  - parapox
    - Miller's nodules (Paravaccinia), 24
    - orf, 24
- PPD-Y intradermal reaction, 4
- praziquantel
  - for cysticercosis, 129
  - for fascioliasis, 130
  - for paragonimiasis, 131
- pregabalin, for post-herpetic neuralgia, 31
- primary cutaneous coccidioidomycosis, 147–148
- primary inoculation tuberculosis (tuberculosis chancre), 67
- progressive hypertrophic familial neuropathy and Hansen's disease, 78
- Propionibacterium acnes*, 262
- ProQuad vaccine, for measles/mumps/varicella, 278
- Prototheca* green seaweed mutant, 174
- Prototheca wickerhamii*, 174
- protothecosis infection, 174–175
- protozoa. *See also* individual *Leishmania* species
  - Chagas' disease, 159–160
  - enteric amebiasis, 121
  - free living amebas, 121–122
  - leishmaniasis, 117. *See also* leishmaniasis mucocutaneous/tegumental leishmaniasis, 160–164
  - in mucous membrane infections
    - leishmaniasis, 296–297
    - trichomoniasis, 296
  - trypanosomiasis, 122–123
    - American trypanosomiasis, 123
    - human African trypanosomiasis, 122–123
- proximal subungual onychomycosis (PSO), 236, 270
- Pseudallescheria boydii*, 113
- pseudoepitheliomatous hyperplasia (in chromomycosis), 99, 114
- pseudolymphoma of the skin, 74
- Pseudomonas aeruginosa*, 19, 189, 214–215, 251, 295, 303
- psoriasis
  - guttate psoriasis, 211, 212
  - impetigo infections from, 261
  - mimicking of
    - by lupus vulgaris, 74
    - by onychomycosis, 53
  - nail dystrophy from, 236
  - pityriasis amiantacea from, 256
  - vs. Hansen's disease lesions, 78
- pubic lice, 318
- Public Health Service (PHS) paucibacillary disease treatment guidelines, 84
- pulmonary tuberculosis, 5
- pustulation (as sign of acute infection), 8
- pyrazinamide
  - for cutaneous TB treatment, 73
  - for pulmonary tuberculosis, 292
- pyrethrin extracts, for pediculosis capitis, 259
- pyrithione zinc shampoo, 256
- quinine, for tularemia, 95
- quinolones
  - for atypical mycobacterioses, 90
  - for cellulitis/erysipelas, 234
- quinupristin/dalfopristin, for MRSA strains, 20
- Rabello, Francisco, 151
- ravuconazole, for mucormycosis, 110
- recalcitrant cutaneous dermatophyte, 47
- “reinfection” tuberculosis, 60
- relapsing fever, 92
- repellants for insects. *See* DEET (N,N-diethyl-3-methylbenzamide)
  - mosquito repellent
- retapamulin ointment, for impetigo, 20
- retinoids (topical)
  - for Bowenoid papulosis, 26
  - for KS, 34
  - for molluscum contagiosum, 229, 264
  - for pseudofolliculitis barbae, 216
  - for verrucae vulgaris/condyloma acuminatum, 203, 228
- Rhabdoviridae* virus, 153
- rhinocerebral mucormycosis, 251
- Rhinocladia aquaspersa* dematiaceous fungus, 98–99, 156
- rhinophycomycosis, 110
- rhinoscleroma, 294
- rhinosporidiosis, 103–104
- Rhinosporidium seeberi*, 103
- Rhipicephalus sanguineus* (Brown dog tick), 323
- Rhizomucor pusillus*, 109
- Rhizopodiformis*, 109
- Rhizopus arrhizus* (*oryzae*), 109
- Rhizopus microsporus var.*, 109
- Rhodnius prolixus* parasite, 160
- ribavirin
  - for chronic HCV, 37
  - for South American hemorrhagic fevers, 153
- Rickettsia rickettsii*, 323
- rickettsial disease, 92, 95, 311
- Ridley-Jopling classification of Hansen's disease, 78–80, 83
- rifampicin
  - for CA-MRSA, 20
  - with clindamycin, for scalp cellulitis, 263
  - for cutaneous TB treatment, 73
  - for multibacillary disease, 84
  - for nasal carriage issues, 21
  - for Old World CL, 144
  - for paucibacillary disease, 84
  - for rhinoscleroma, 294
- rifampin
  - for actinomycetoma management, 98
  - for atypical mycobacteria, 244
  - for cat-scratch disease, 215
  - for cutaneous tuberculosis, 73
  - for ehrlichiosis, 215
  - for leprosy, 293
  - for meningococcal disease, 323
  - for multibacillary disease, 84
  - for pulmonary tuberculosis, 292
- Rig Veda, 59
- RNA retroviruses in mucous membrane infections
  - HIV, 284
  - human T-lymphotropic virus, 284
- RNA viruses
  - flaviviruses: hepatitis C, 37
  - in mucous membrane infections, 281–284
    - hand-foot-and-mouth disease, 281–282
    - herpangina, 282–283
    - measles, 283
    - mumps, 283
    - rubella, 283–284
  - paramyxoviruses: rubeola/measles, 36–37
  - picornaviruses
    - enteroviruses
      - hand, foot, and mouth disease, 35–36
    - hepatovirus: hepatitis A, 36
    - herpangina, 36

## 344 — Index

- RNA viruses (cont.)  
 retroviruses: HIV, 37–38  
 togaviruses: rubella (German measles), 37
- Rocky Mountain spotted fever (RMSF), 92, 323–324  
 clinical manifestations, 324  
 diagnosis, 324  
 historical background, 322  
 management, 324
- Roger of Palermo, 275
- Rokintansky, Carl, 59
- ROM therapy (rifampin 600 mg, ofloxacin 400 mg, minocycline 100 mg), 84
- roseola infantum (HHV 6), 33  
 bone marrow transplant patients and, 33  
 clinical manifestations, 33  
 diagnosis, 33  
 HIV and, 33  
 in mucous membrane infections, 279–280  
 treatment, 33
- rubella (German measles), 37  
 clinical manifestations, 37  
 congenital, 223–224  
 diagnosis, 37  
 treatment, 37
- rubeola (measles), 36–37  
 clinical manifestations, 36  
 diagnosis, 37  
 in mucous membrane infections, 283  
 ProQuad vaccine for, 278  
 treatment, 37
- Rudolph, Max, 151
- Saksenaia vasiformis*, 109
- salicylates, 277, 278
- salicylic acid  
 for Butcher's warts, 26  
 for common warts, 25  
 for tinea nigra, 154–155  
 for verruca, 228  
 for verruca vulgaris/condyloma acuminatum, 25, 203
- sandfly-borne diseases, 92, 136–137, 137. *See also* Old World cutaneous leishmaniasis
- Sappinia diploidea*, 121
- sarcoidal granulomas, 6
- Sarcoptes scabiei var. hominis*, 260, 317
- scabies, 317–318  
 causative agents, 193  
 diagnosis, 2  
 in HIV infection, 193  
 vs. onchocerciasis, 124
- scalp infections  
 bacterial infections  
 eosinophilic pustular folliculitis, 261  
 erysipelas/scalp cellulitis, 262  
 folliculitis, 260  
 impetigo, 261–262  
 staphylococcal folliculitis, 260–261  
 fungal infections  
 piedra, 258–259  
 pityriasis amiantacea, 256  
 pityriasis capitis, 255–256  
 seborrheic dermatitis, 255–256  
 historical background, 255  
 from intrauterine fetal monitoring devices, 262  
 parasitic infections  
 demodicidosis, 260  
 pediculosis capitis, 259–260  
 scabies, 260  
 pitfalls and myths, 264–265  
 postoperative infections, 262  
 with presumed bacterial etiology  
 acne miliaris necrotica, 262  
 dissecting cellulitis, 262–263  
 erosive pustular dermatosis, 263  
 folliculitis decalvans, 262–263  
 folliculitis keloidalis (acne keloidalis), 262  
 scalp anatomy, 255  
 in transplant patients, 264  
 unusual infections  
 mycobacterial infection, 264  
 syphilis, 263–264  
 viral infections  
 herpes viral infections, 264  
 molluscum contagiosum, 264  
 warts, 264
- Scedosporium apiospermum*, 113
- Schistosoma hematobium*, 130
- Schistosoma japonicum*, 130
- Schistosoma mansoni*, 130
- schistosomal dermatitis. *See* cercarial dermatitis (swimmer's itch)
- schistosomiasis, 130, 150
- Scopulariopsis brevicaulis*, 219, 236, 270, 271
- Scopulariopsis* spp., 113
- scorpions, 231
- Scrofulin intradermal reaction, 4
- scrofuloderma, 59, 64, 74
- scrotal paragonimiasis, 131
- Scytalidium dimidiatum*, 272
- sea bather's eruption, 171–172
- sea urchins, reactions to, 172–173
- seborrheic dermatitis, 255–256
- secondary syphilis, 74
- selenium sulfide  
 for piedra, 259  
 for tinea capitis, 51, 217
- selenium sulfide shampoos, 51, 217, 256
- sexually transmitted diseases (STDs) and HIV skin infections  
 anogenital warts, 319  
 chancroid, 309, 312–313  
 genital bite wounds, 316–317  
 genital herpes, 318–319  
 gonorrhea, 310, 315–316  
 granuloma inguinale (donovanosis), 190–191, 309, 314–315  
 historical background, 309–310  
 lymphogranuloma venereum (LGV), 191, 309, 313–314  
 pubic lice, 318  
 scabies, 317–318  
 syphilis, 190, 309, 310–312 (*see also* syphilis)
- Silva, Flaviano, 151
- skin surgical site infections (SSIs)  
 definition/classification, 303–304  
 historical background, 303  
 intrinsic risk factors, 304  
 management/prevention  
 antibiotic prophylaxis, 306  
 aseptic technique, 305  
 surgical site care, 305–306  
 procedure-related risk factors  
 bleeding during procedure, 304–305  
 location, 304  
 type of lesion, 304  
 type of procedure and repair, 304  
 “Slapped Cheeks.” *See* parvovirus B19
- sleeping sickness. *See* human African trypanosomiasis (sleeping sickness)
- smallpox virus  
 clinical manifestations, 23  
 vaccination for, 23, 229
- sodium stibogluconate (Pentostam<sup>®</sup>), for leishmaniasis, 121, 143, 164
- South American blastomycosis (*P. braziliensis*). *See* paracoccidioidomycosis (South American blastomycosis)
- South American hemorrhagic fevers, 153
- sparganosis, 129
- spectinomycin, for gonorrhea, 315–316
- Spherulin test, 4
- spiders, 231
- spirochetes (in children)  
 endemic treponematoses, 215–216  
 Lyme disease, 215
- Spirometra* spp., 129
- sponges and aquatic dermatoses, 174
- Sporothrix schenckii* dimorphic fungus, 155
- sporotrichosis, 6, 64, 100–102  
 cutaneous forms, 100–101  
 diagnosis, 101–102, 155  
 extra-cutaneous forms, 101  
 treatment, 102  
 zoonotic transmission, 155
- Sporotrichum*, 7
- squamous cell carcinoma (SCC)  
 anogenital, 187  
 from chronic sun exposure, 203  
 differentiation from tuberculosis, 65  
 epidermoid, 99  
 lesion excision, 303  
 oral, 280  
 PS as suggestive of, 114  
 subungual, 209
- squamous cell carcinoma in situ (SCCIS), 203
- staphylococcal scalded skin syndrome (SSSS), 196, 212–213
- staphylococcal scarlet fever, 196
- staphylococcal toxic shock syndrome, 19, 324–325  
 clinical manifestations, 325  
 diagnosis, 325  
 historical background, 322  
 management, 325  
 pitfalls and myths, 327



- staphylococcus, 293  
*Staphylococcus aureus*, 18  
 blistering dactylitis from, 212  
 carbuncles caused by, 19  
 cellulitis from, 249  
 conditions predisposing to colonization, 21  
 ecthyma caused by, 19  
 folliculitis from, 189, 234  
 furunculosis from, 234  
 impetigo from, 19, 211, 234, 238  
 orbital/periorbital cellulitis from, 213  
 perianal streptococcal dermatitis from, 212  
 SSSS from, 212  
 staphylococcal TSS from, 322, 325  
 surgical skin infections from, 303  
 in transplant recipients, 195–196  
*Staphylococcus epidermis*, 189, 212  
*Staphylococcus pneumoniae*, 196, 213  
 starfish, reactions to, 173  
 Steven-Johnson syndrome, 45, 185, 258  
*Stichodactyla gigantea* anemone, 170  
 stinging insects, 232  
 streptococcal toxic shock syndrome, 19, 325–327  
 clinical manifestations, 326  
 diagnosis, 326  
 historical background, 322  
 management, 326–327  
 pitfalls and myths, 327  
*Streptococcus aureus*, 250, 262  
*Streptococcus mutans*, 293  
 streptococcus pharyngitis, 293  
*Streptococcus pyogenes*, 18, 250, 262, 293, 325–326  
 ecthyma caused by, 19  
 erysipelas caused by, 19  
 impetigo caused by, 19  
 orbital/periorbital cellulitis from, 213  
*Streptococcus viridians*, 293  
*Streptomyces somaliensis*, 97  
 streptomycin  
 for actinomycetomas, 98  
 for tularemia, 95  
*Strongyloides stercoralis*, 125, 126  
 subcutaneous phaeohyphomycosis, 113  
 subcutaneous/deep mycoses  
 chromoblastomycosis, 98–100, 156 (*see also* chromoblastomycosis)  
 lobomycosis, 151, 157 (*see also* lobomycosis)  
 mycetoma, 97–98, 156–157  
 paracoccidioidomycosis, 158–159 (*see also* paracoccidioidomycosis)  
 rhinosporidiosis, 103–104  
 sporotrichosis, 100–102, 155–156 (*see also* sporotrichosis)  
 subungual proximal superficial onychomycosis, 191  
 sulconazole nitrate 1%, for tinea pedis/manuum, 47  
 sulfadiazine  
 for *Balamuthia mandrillaris*, 122  
 for congenital toxoplasmosis, 222  
 sulfamethoxazole-trimethoprim (SMZ-TMP), for paracoccidioidomycosis, 108, 159  
 sulfur preparations, for scabies, 260  
 sulfur shampoos, 256  
 sunscreen  
 on lips, for herpes labialis, 240, 277  
 for warts, 203  
 superficial mycoses  
 black piedra, 154  
 piedra nigra, 151  
 tinea nigra, 154–155  
 white piedra, 153–154  
 suppurative granulomas, 6  
 suppurative/granulomatous inflammatory infiltrate (in chromomycosis), 99  
 suramin, for trypanosomiasis, 123  
 surgical excision  
 for anogenital warts, 319  
 for chromoblastomycosis, 156  
 for coenurosis, 130  
 for condyloma acuminata, 188  
 for echinococcosis, 129  
 for genital warts, 319  
 for KS, 202  
 for lobomycosis, 103  
 for mucormycosis, 110  
 for oral florid papillomatosis, 281  
 for protothecosis, 175  
 for rhinosporidiosis, 104  
 of solitary KS lesions, 34  
 Sweet's syndrome (acute febrile neutrophilic dermatosis), 146  
 swimmers itch. *See* cercarial dermatitis  
 sympathetic nerve blockade, for post-herpetic neuralgia, 31  
 syphilis, 190, 275, 309, 310–312  
 clinical manifestations, 310  
 and secondary/tertiary hair loss, 263–264  
 systemic corticosteroids  
 for candidal infection, 284  
 for Lucio's phenomenon, 85  
 for Sweet's syndrome, 146  
 systemic mycosis  
 blastomycosis (North American), 105–106  
 chronic form (adult type), 107–108  
 cryptococcosis, 111–112  
 entomophthoromycosis, 110–111  
 histoplasmosis, 104–105  
 hyalohyphomycosis, 113–114  
 mucormycosis, 109–110  
 paracoccidioidomycosis (S.A. blastomycosis), 106–109  
 chronic form (adult type), 107–108  
 residual/sequel form, 108–109  
 phaeohyphomycosis, 112–113  
 residual/sequel form, 108–109  
 zygomycosis, 109  
*T. pallidum*, 3, 216, 292, 313, 320  
 tacrolimus (topical), for erosive pustular dermatosis of scalp, 263  
*Taenia crassiceps*, 129  
*Taenia multiceps*, 129  
*Taenia serialis*, 129  
 tar shampoos, 256, 256  
*Tedania anhelans* sponge, 174  
*Tedania ignis* fire sponge, 174  
 tegmental leishmaniasis. *See* mucocutaneous/tegmental leishmaniasis  
 teicoplanin, for MRSA strains, 20  
 telogen effluvium, 256  
 tenderness (as sign of acute infection), 8  
 terbinafine (oral)  
 for adult dermatophyte onychomycosis, 47  
 adverse effects, 47  
 for black piedra, 259  
 for diabetes mellitus, 47  
 for entomophthoromycosis, 111  
 mycological cure rates in dermatophyte onychomycosis, 52  
 for onychomycosis, 191, 236  
 for sporotrichosis, 102  
 for tinea capitis, 51, 51, 217, 258  
 for tinea corporis/cruris/faciei, 50–51  
 for tinea imbricata (tokelau), 219  
 for tinea pedis/manuum, 47–50  
 for tinea unguium, 52, 191, 236, 237  
 for transplant patients, 47  
 terbinafine (solution, cream, gel, spray), for pityriasis versicolor, 53  
 tertiary syphilis, 74  
 tetanus, 294, 296, 317  
 tetanus, diphtheria, acellular (DTaP) vaccine, 294  
 tetanus vaccination, 294  
 tetracyclines  
 for acne miliaris necrotica, 262  
 for atypical mycobacterioses, 90  
 for CA-MRSA, 20  
 for endemic treponematoses, 216  
 for folliculitis keloidalis, 262  
 for rhinoscleroma, 294  
 for syphilis, 312  
 thermocoagulation, for condyloma acuminata, 188  
 ThermoMed™ device, for Old World CL, 142–143  
 thrush (oropharyngeal candida)  
 in children, 221  
 in elderly people, 235  
 tick-borne diseases, 92  
 tigecycline, for MRSA strains, 20  
 Tilbury, William, 59  
 tinea capitis. *See also* dermatophytosis  
 antifungal medications for, 51  
 black-dot tinea capitis, 257  
 in children, 217–218  
 oral vs. topical medication, 45  
 of the scalp, 256–258  
*Tinea corporis*, 191  
 tinea corporis/cruris/faciei, 50–51, 78  
 tinea cruris, in children, 218  
 tinea imbricata (tokelau), in children, 219  
 tinea incognita, 2, 218  
 tinea nigra, 154–155, 220

## 346 — Index

- tinea pedis/manuum, 47–50, 236–237  
*Tinea rubrum*, 191  
 tinea unguium, 42, 51–52  
   antifungal medications for, 51–52  
   in children, 218–219  
   in elderly patients, 236  
   mimicking by other conditions, 53  
   North American prevalence, 42  
   oral vs. topical therapy, 45  
   subtypes of, 236  
   white onychomycosis, 2  
 tinidazole  
   for enteric amebiasis, 121  
   for trichomoniasis, 296  
 toenail onychomycosis, 51, 52  
 togaviruses. *See* rubella (German measles)  
 toll-like receptor-(TLR)-2 association with  
   lepromatous leprosy, 77  
 tolnaftate solution, for tinea unguium  
   (onychomycosis), 219  
 topical clindamycin, 20, 214  
 topical mupirocin  
   for localized impetigo, 20  
   for nasal carriage issues, 21, 196  
 topical therapy, agent formulary/guidelines,  
   11  
 total dystrophic onychomycosis, 272  
 toxic shock syndrome (TSS), 196, 305.  
   *See also* staphylococcal toxic shock  
   syndrome; streptococcal toxic shock  
   syndrome  
 Transcription Mediated Amplification  
   (TMA), 5  
 transplant recipients, bacterial/viral diseases  
   bacillary angiomatosis, 197  
   B-hemolytic streptococcus, 196–197  
   gram-negative bacilli (GNB), 197  
   historical background, 195  
   necrotizing fasciitis, 197  
   nocardiosis, 198  
   *Staphylococcus aureus*, 195–196  
   *vibrio vulnificus*, 197  
 transplantation-related viral disease  
   cytomegalovirus, 201–202  
   Epstein-Barr virus, 201  
   herpes simplex virus, 1 and 2, 199–200  
   Herpetoviridae (human herpes viruses),  
     199  
   human herpes virus-8, 202  
   human papilloma virus, 203  
   molluscum contagiosum, 202–203  
   varicella-zoster virus, 200–201  
 trematodes, 130–131  
   fascioliasis, 130  
   paragonimiasis, 131  
   schistosomiasis, 130  
 treponemal serology test, 4  
 tretinoin (topical), for molluscum  
   contagiosum, 187  
*Triamota infestans* arthropod, 160  
*Trichinella britovi*, 127  
*Trichinella murrelli*, 127  
*Trichinella native*, 127  
*Trichinella nelsoni*, 127  
*Trichinella papuae*, 127  
*Trichinella pseudospiralis*, 127  
*Trichinella solium*, 128  
*Trichinella spiralis*, 127  
 trichinellosis, 127–128  
   diagnosis, 128  
   treatment, 128  
 trichloroacetic acid (80%)  
   for anogenital warts, 319  
   for Butcher's warts, 26  
   for common warts, 25  
   for condyloma acuminata, 26, 188  
   for molluscum contagiosum, 23  
*Trichoderma* spp., 113  
 trichomycosis axillaris, in children, 214  
 Trichophyitin test, 4  
*Trichophyton mentagrophytes*, 243, 257–258  
*Trichophyton rubrum*, 243, 270–271  
*Trichophyton schoenleinii*, 256, 258  
*Trichophyton soudanense*, 272  
*Trichophyton tonsurans*, 256–258  
*Trichophyton verrucosum*, 257–258  
*Trichophyton violaceum*, 256, 272  
*Trichosporon asahii*, 112, 258  
*Trichosporon asteroides*, 258  
*Trichosporon beigelii* yeast, 153  
*Trichosporon cutaneum*, 258  
*Trichosporon inkin*, 258  
*Trichosporon interdigitale*, 271  
*Trichosporon mucoides*, 258  
*Trichosporon ovoides*, 258  
 triclabendazole, for fascioliasis, 130  
 triclosan, for skin colonization issues, 21  
 tricyclic antidepressants  
   for herpes zoster, 235  
   for post-herpetic neuralgia, 31  
 trifluridine, for herpes simplex virus, 200  
 trimethoprim/sulfamethoxazole  
   (TMP-SMX)  
   for atypical mycobacterioses, 90  
   for CA-MRSA, 20  
   for cat-scratch disease, 215  
   for granuloma inguinale, 191, 315  
   for nocardiosis, 198  
 tropical infections  
   in athletes (ulcers), 240  
   general information, 150  
   historical background, 150–151  
   pitfalls and myths, 164–165  
   protozoa  
   Chagas' disease, 159–160  
   mucocutaneous/tegmental  
     leishmaniasis, 160–164  
   subcutaneous/deep mycoses  
   chromoblastomycoses, 156 (*see also*  
     chromoblastomycosis)  
   lobomycosis, 151, 157–158 (*see also*  
     lobomycosis)  
   mycetoma, 97–98, 156–157  
   paracoccidioidomycosis, 158–159 (*see*  
     *also* paracoccidioidomycosis)  
   sporotrichosis, 155 (*see also*  
     sporotrichosis)  
   superficial mycoses  
   black piedra, 154  
   piedra nigra, 151  
   tinea nigra, 154–155  
   white piedra, 153–154  
   viruses  
   Barmah Forest virus (BFV), 152–153  
   Dengue fever, 92, 95, 151–152  
   hemorrhagic fevers, 151  
   Lassa fever, 153  
   Marburg/Ebola virus, 153  
   South American hemorrhagic fevers,  
     153  
   West Nile virus (WNV), 152  
   Yellow fever, 152  
*Trypanosoma cruzi* parasite, 159  
*Trypanosomatidae* family, 161, 117. *See also*  
   *Leishmania* entries  
 trypanosomiasis, 92, 122–123, 150  
   American trypanosomiasis, 123  
   human African trypanosomiasis,  
     122–123  
*Trypanosomiasis brucei gambiense*, 122  
*Trypanosomiasis brucei rhodesiense*, 122  
*Trypanosomiasis cruzi*, 122  
 tuberculids, 68  
 Tuberculin test (PPD/purified protein  
   derivative), 4  
 tuberculoid granulomas, 6, 7, 62, 70. *See also*  
   leishmaniasis; sporotrichosis  
 tuberculosis. *See* cutaneous tuberculosis;  
   extrapulmonary tuberculosis;  
   *Mycobacterium tuberculosis*  
 tuberculosis (TT) leprosy, 79  
 tuberculosis chancre (primary inoculation  
   tuberculosis), 67  
 tuberculosis cutis miliaris acuta generalisata  
   (acute disseminated miliary  
   tuberculosis), 67  
 tuberculosis gumma, 68, 74  
 tuberculosis of the breast, 72  
 tuberculosis verrucosa cutis (warty  
   tuberculosis), 60, 65, 74, 78  
   vs. Hansen's disease lesions, 78  
 tuberculous lymphadenitis with lupus  
   vulgaris, 63  
 tularemia, 67, 74, 92  
 tumor necrosis factor A (TNFA) association  
   with lepromatous leprosy, 77  
 ulceration (as sign of acute infection), 8  
*Uncinaria stenocephala*, 125, 176  
 uncomplicated skin and skin structure  
   infections (uSSSIs). *See also*  
   *Staphylococcus aureus*; *Streptococcus*  
   *pyogenes*  
   abscesses/carbuncles/furuncles, 17  
   cellulitis, 17–18  
   diagnosis of, 20  
   ecthyma, 18  
   epidemiology of, 19–20  
   erysipelas, 18  
   folliculitis, 17  
   historical background, 18–19  
   impetigo, 18  
   therapies for, 20–21  
   unilateral regional lymphadenopathy, 74  
   urethral secretions, 2

- uSSSIs. *See* uncomplicated skin and skin structure infections
- vaccinations  
 for Argentinian hemorrhagic fevers, 153  
*Bacillus Calmette-Guerin* (BCG), 4, 62, 65, 72–73  
 for diphtheria, 294  
 measles, 37  
 for measles, mumps, rubella (MMR), 278, 283  
 meningococcal conjugate vaccine A, C, Y, W-135, 323  
 smallpox virus, 23, 229  
 varicella zoster virus, 31–32, 201  
 for Yellow fever, 152
- vaccinia  
 in children, 229–230  
 clinical manifestations, 24  
 treatment, 24
- vaginal candidiasis, 47, 248, 252
- valacyclovir  
 for congenital herpes simplex, 30  
 for genital herpes, 319  
 for herpes simplex virus, 200, 277  
 for herpes zoster, 31, 235, 264  
 for HSV, 186  
 for HSV-1/HSV-2, 29  
 for oral hairy leukoplakia, 187  
 for varicella zoster virus, 31, 201
- valganciclovir, for CMV, 33, 187, 202, 279
- vancomycin  
 for cellulitis/erysipelas, 234  
 for impetigo/folliculitis/furunculosis, 234–235  
 for MRSA strains, 20  
 for *S. aureus*, 196  
 for staphylococcal TSS, 325
- varicella zoster virus (HHV-3), 5, 30  
 in acute exanthem of HIV infection, 186–187  
 children's treatment, 31  
 in mucous membrane infections, 278  
 neonatal varicella, 31  
 in transplantation recipients, 200–201
- vasculitic appearance (as sign of acute infection), 8
- Vedic scriptures, 59
- verrucous carcinoma  
 treatment, 27  
 types of  
 epithelioma cuniculatum, 26–27  
 giant condyloma of Buschke and Lowenstein, 27  
 oral florid papillomatosis, 27
- verrucous zoster, 186
- vesiculation (as sign of acute infection), 8
- Viana, Gaspar, 150, 160–161
- Villemin, Jean Antoine, 59
- vinblastine, for KS, 34, 202, 280
- viral disease in transplantation  
 cytomegalovirus, 201–202  
 Epstein-Barr virus, 201  
 herpes simplex virus, 1 and 2, 199–200  
 herpesviridae (human herpes viruses), 199  
 human herpes virus-8, 202  
 human papilloma virus, 203  
 molluscum contagiosum, 202–203  
 varicella-zoster virus, 200–201
- viral encephalitis, 92
- viral hemorrhagic fevers, 92
- viral infections in athletes  
 herpes simplex  
 activation, 240  
 skin-to-skin transmission, 240–241
- molluscum contagiosum, 241–242  
 verruca, 242
- Virchow, Rudolph, 59, 59
- visceral leishmaniasis, 4
- Vitamin A  
 for measles, 37  
 topical, for oral hairy leukoplakia, 279
- volume expanders, for Dengue fever, 152
- voriconazole  
 with amphotericin B, for hyalohyphomycosis, 113–114  
 for aspergillosis, 288
- Wangiella dermatitidis*, 98–99, 113
- warmth (as sign of acute infection), 8
- warts. *See* Butcher's warts; common warts (*verruca vulgaris*); condyloma acuminatum (genital warts); flat warts (*verrucae plana*); palmoplantar warts (*myrmecia*)
- warty tuberculosis (tuberculosis verrucosa cutis), 60, 65, 74
- Waterhouse-Friderichsen syndrome (fulminant meningococcal disease), 323
- West Nile virus (WNV), 92, 152  
 clinical manifestations, 152  
 diagnosis/treatment, 152  
 mosquito vectors, 152
- white piedra, 153–154, 220, 258
- white superficial onychomycosis (WSO), 236, 271–272
- Whitfield's ointment  
 for erythrasma, 214  
 for tinea imbricata (tokelau), 219
- Willan, Robert (British Dermatology founder), 59
- World Health Organization (WHO)  
 classification of Hansen's disease, 76, 80  
 hepatitis C estimates, 37  
 leishmaniasis data  
 mucocutaneous/tegmental leishmaniasis, 160  
 Old World cutaneous leishmaniasis, 135–136  
 paucibacillary disease treatment guidelines, 84  
 TB infection estimates, 59
- Wuchereria bancrofti*, 123
- Yellow fever, 151, 152  
 clinical findings, 152  
 diagnosis, 152  
 mosquito vectors, 152  
 treatment, 152
- zinc pyrithione, for tinea capitis, 51
- zinc sulfate, for Old World CL, 144
- zoonosis infection, 126, 161. *See also* American trypanosomiasis; leishmaniasis
- zygomycosis, 96, 103, 109, 209